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Introduction: Cholesterol metabolism in the brain is implicated in the development of 
Alzheimer’s disease (AD). Understanding the relationship between markers of brain cholesterol 
metabolism and the structural changes occurring in the aging brain has particular public health 
relevance to the treatment and prevention of AD.  
Methods: This dissertation consists of a systematic review of the literature and two papers of 
original research. Our systematic review: critically evaluates the literature regarding brain 
cholesterol metabolism and AD, identifies gaps in our current understanding, and proposes 
directions for future research. The two papers of original research were designed to address these 
gaps in knowledge. We examined the relationship between plasma oxysterol metabolites and 
cerebrovascular disease, amyloid deposition in the brain, and incident cognitive impairment 
using two longitudinal cohorts of older adults with extensive characterization of cognition and 
brain structure. Quantitative marker of brain structure were prior to clinical disease using 
magnetic resonance imaging (MRI) and positron emission tomography (PET). 
Results: Our review found inconsistent associations between brain-derived plasma oxysterols 
and AD. Epidemiological design issues and methodological limitations may explain these 
conflicting results; these include: residual confounding, lack of temporal of associations, and 
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inconsistent direction of associations resulting from stage of the disease at which oxysterols were 
measured. A major methodological limitation is the scarcity of objective measures to quantify 
underlying structural changes occurring the brain. Our original research examined the 
longitudinal association between oxysterols, cognition and brain imaging markers in non-
demented older adults. We found higher levels of brain-derived oxysterols were associated with 
MRI markers of cerebrovascular disease and a greater risk of cognitive impairment over 8 years 
of follow-up. Furthermore, we found that lipid-lowering drugs modify the association between 
plasma oxysterols levels and amyloid deposition in the brain, visualized using PET.  
Conclusions: There are important relationships between brain degeneration, cholesterol 
metabolism and dementia that need to be better understood. Brain-derived metabolites of 
cholesterol appear to be elevated in the early stages of disease prior to the onset of cognitive 
impairment. Brain-derived plasma oxysterols may be an important marker of underlying 
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1.1 INTRODUCTION TO REVIEW 
Studies examining cholesterol synthesis as an intervention target for dementia make the 
assumption that altering cholesterol levels in the circulation correlate directly with cholesterol 
levels in the brain. In fact, the measurement of brain cholesterol in vivo remains difficult because 
the presence of the blood brain barrier (BBB) ensures the near complete separation of cholesterol 
in the body from cholesterol produced in the brain. Cholesterol’s inability to cross the BBB 
makes total blood cholesterol a surrogate marker with little potential relevance to the 
brain(Bjorkhem 2006). Other more proximate markers of cholesterol concentrations in the brain 
exist. The brain-derived oxysterol, 24S-hydroxycholesterol (24-OHC) crosses the BBB directly 
by diffusion and is the primary means by which excess cholesterol is eliminated from the 
brain(Bjorkhem 2006). The ability of 24-OHC to cross the BBB, whereas cholesterol cannot, 
makes 24-OHC a noninvasive and more proximate marker of cholesterol homeostasis occurring 
in the brain(Leoni 2009).   
In the past decade, there has been a growing interest in examining the association 
between brain-derived oxysterol, 24-OHC and neurodegenerative diseases including vascular 
dementia, Alzheimer’s disease and mild cognitive impairment. Previous studies suggest that 24-
OHC is a marker of the number of metabolically active neurons in the brain and is associated 
with the diagnosis and severity of dementia and other neurodegenerative diseases.  
This review critically evaluates evidence as to whether plasma 24-OHC is a suitable 
marker of dementia and it proposes directions for future studies of objective measures of brain 
degeneration. Specifically, we propose that: 1) the brain-derived oxysterols, 24-OHC, is a more 
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proximate marker of cholesterol homeostasis in the brain than the level of total cholesterol in the 
circulation; 2) excess cholesterol in the brain is likely a by-product of cell membrane disruption; 
and 3) excess brain cholesterol leads to increased 24-OHC levels; 4) excess brain cholesterol 
contributes to amyloid plaque formation and the risk of dementia; 5) 24-OHC is a potential 
marker of the changes in cholesterol homeostasis occurring early in the dementia process. This 
review is organized into three major sections. First, we review cholesterol synthesis and 
metabolism in the brain. Then, we provide a detailed overview of the issues regarding the 
measurement of 24-OHC as a marker of cholesterol metabolism in the context of age-related 
cognitive impairment. Finally, we discuss these findings in the context of potential mechanisms 
linking excess cholesterol in the brain to the development of dementia.  
1.2 CHOLESTEROL METABOLISM IN THE BRAIN 
Maintaining cholesterol homeostasis in the brain is vitally important to its proper 
functioning. Cholesterol deficiency in the brain will inhibit neuronal growth(Mauch and Nagler 
2001) and integrity of the connection between neurons(Pfrieger 2003). Conversely, excess 
cholesterol levels in the body are associated with increased AD risk(Kivipelto and Helkata 2002) 
and demonstrate AD pathology in vivo(Reid, Urano et al. 2007).    
The brain is the richest organ in cholesterol content, containing about 25% of the total 
amount of cholesterol in the body(Snipes and Suter 1997). Efficient cholesterol synthesis and 
metabolism is critically important to maintaining the function of the entire brain(Snipes and 
Suter 1997). The vast majority (70-80%) of the cholesterol in the brain resides in the myelin. 
Axonal myelination lowers the action potential of the nerve, speeding the propagation of the 
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signal along the length of the axon(Bartzokis 2004) and increasing the connectivity between 
neurons. Myelin is composed mostly of fat (70%), and 28% of this fat is cholesterol. Thus, a 
major function of brain cholesterol homeostasis is to maintain the insulatory properties of the 
myelin(Pfrieger 2003).  
Highly efficient mechanisms have evolved for maintaining constant levels of cholesterol 
in the brain. The most important of these is the isolation of brain-derived cholesterol by the 
BBB(Bjorkhem 2006). Cholesterol is unable to cross the BBB directly, thus ensuring the 
complete separation of cholesterol in the circulation from cholesterol synthesized in the brain. 
The BBB isolates brain cholesterol from fluctuations of cholesterol in the periphery. As a result, 
both the de novo synthesis and the metabolism of cholesterol are solely responsible for 
cholesterol homeostasis in the brain(Leoni 2009).  
1.2.1 Synthesis of cholesterol in the brain and transport via ApoE. 
Cholesterol synthesis occurs at relatively low rates in the brain, with the majority of 
production believed to come from the glial cells(Pfrieger 2003; Dietschy and Turley 2004). 
Following synthesis, cholesterol is secreted from the glial cells and internalized within ApoE for 
delivery to the neurons(Pfrieger 2003). Cholesterol has been shown to play important roles in 
central nervous system development and synaptic plasticity. In vitro studies indicate cholesterol 
is a synapse-promoting factor when carried by ApoE(Mauch DH and K 2001). ApoE is involved 
in the distribution and recycling of cholesterol during neuronal growth and death. Neurons meet 
their cholesterol requirements via ApoE dependant mechanisms(Pfrieger 2003). 
Cholesterol-rich ApoE bind primarily to a group of receptors known as the LDLR family. 
Over ten receptors have now been identified as members of the LDLR family. They all bind 
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ApoE and a diverse array of ligands to mediate their signaling and transport across plasma 
membranes(Bu 2009). LDLR and LRP1 are the most prominent members of the LDLR family 
and also the main ApoE metabolic receptors in the brain(Abbott, Sharp et al. 1997). As the 
prototype of this family, LDLR is the main receptor for cholesterol homeostasis(Rapp, Gmeiner 
et al. 2006). LDLR is more prominently expressed in glia than in neurons. Data from mice gene 
deletion models suggest that LDLR gene increases ApoE levels in the brain parenchyma and 
CSF, suggesting that it causes impaired metabolism of ApoE and cholesterol recycling(Fryer, 
Demattos et al. 2005). LRP1 is expressed highly on the surface of neurons and to a lesser degree 
in glia. Deletion of LRP1 gene increases ApoE and decreases cholesterol concentrations in the 
mouse brain(Fryer, Demattos et al. 2005). 
Once delivered to the neuron by ApoE, cholesterol is internalized and incorporated into 
the neuronal membranes, including the myelin. Neurons meet their cholesterol requirements via 
local synthesis and ApoE-dependant tranport(Pfrieger 2003). Depending on the requirements of 
the neuron, cholesterol is either catabolized into cholesterol esters for storage in plasma 
membranes and myelin or metabolized into oxysterols for elimination(Brown and Theisler 
2004).  
1.2.2 The brain’s reaction to excess cholesterol and the potential link to Alzheimer’s 
disease.  
Experimental animal and cell-culture studies suggest that cholesterol metabolism in the 
brain can modify amyloid production(Kuller 2007). Bartzokis recently proposed a model of 
Alzheimer’s disease (AD) pathology that is linked to cholesterol metabolism(Bartzokis 2009). 
The neuropathological profile of AD consists of deposition of beta amyloid (Aβ) in the form of 
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neuritic plaques and by neurofibrillary tangles in soluble deposits of hyperphospholated 
tau(Reiss 2005; Blennow and de Leon 2006). Bartzokis’ model proposes the breakdown of the 
myelin as the instigating event of amyloid formation and deposition. This myelin model reframes 
key observations of the AD process, such as: axonal transport disruptions, formation of axonal 
swellings/sphenoids, neuritic plaques, and proteinaceous deposits, including  Aβ and tau, as by-
products of homeostatic myelin repair processes(Bartzokis 2004). In vitro studies show that 
membranes containing high levels of cholesterol are more likely to lead to a primary cleavage of 
the amyloid precursor protein (APP) by β-secretase leading to increased Aβ production and 
deposition surrounding the neuron(Fassbender and Stoick 2002). The deposition and aggregation 
of neuritic plaques and neurofibrillary tangles will in turn lead to widespread loss of neuronal 
funtion and loss of synapses(Brown and Jessup 2009). As the branching of the neuron decreases, 
so does the plasma membrane and myelin. Because cholesterol is so abundant in the plasma 
membrane and myelin, synaptic degeneration will in turn cause excess cholesterol release(Brown 
and Jessup 2009). We propose that there is a feed-forward relationship connecting myelin 
breakdown, excess cholesterol in the brain, the formation of Aβ plaques, and neuronal death 








Another link between cholesterol metabolism and AD pathology rests at the level of the 
ApoE. Besides transporting cholesterol from the glial cells to the neurons, ApoE is also a Aβ 
chaperone. There are strong and important consequences of ApoE binding Aβ. First, the region 
of ApoE that is responsible for Aβ binding overlaps with the cholesterol-binding 
region(Tamamizu-Kato, Cohen et al. 2008). Second, the binding of Aβ to ApoE also changes the 
ability of ApoE to bind cholesterol(Tamamizu-Kato, Cohen et al. 2008). Thus, Aβ peptides can 
interfere with the normal function of ApoE in brain lipid metabolism and contribute to AD 
pathogenesis. This suggests that the efficient function of ApoE as a cholesterol carrier protein 
may be involved in its effect on AD risk(Wollmer 2010). Additionally, the capacity of the three 
isoforms of ApoE to mediate cholesterol efflux to neuronal cells correlates inversely with their 
effect on AD risk (ApoE-4≤ ApoE-3<ApoE-2)(Michikawa, Fan et al. 2000). Importantly, ApoE-
4 allele is the primary genetic risk factor for early age at onset of Alzheimer’s disease 
(AD)(Richard and Amoyuel 2001). The ApoE gene has been estimated to account for 65% of all 
sporadic cases of AD(Richard and Amoyuel 2001). The discovery that the ApoE-4 allele is the 
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primary genetic risk factor for early age at onset of Alzheimer’s disease (AD) has renewed 
interest in the relationship between cholesterol metabolism and the risk of AD and dementia.  
1.2.3 Production of 24 OHC as a means to eliminate excess cholesterol in the brain.  
Cholesterol bound by ApoE can be eliminated from the brain via the cerebrospinal fluid 
(CSF)(Shafaati, Solomon et al. 2007) along the interstitial fluid (ISF) drainage pathway, through 
the blood-brain barrier (BBB), where it then enters the circulation or undergo proteolytic 
degradation upon delivery to lysosomes(Bu 2009). Until recently, ApoE-dependant elimination 
was the only mechanism known to eliminate cholesterol from the brain(Bjorkhem 2006). 
However, the rate of elimination via this route is less than 1% or approximately 1mg per 24 
hours(Bjorkhem and Lutjohann 1998). If this were the only mechanism of elimination, the half-
life of cholesterol in the brain would be about 50 years(Bjorkhem and Lutjohann 1998).  
The other 99% of excess cholesterol in the brain is eliminated by the enzyme-dependant 
oxidation of excess cholesterol into oxysterols(Bjorkhem 2006). Oxidization of cholesterol at the 
24-position, forming 24S-hydroxycholesterol (24-OHC), occurs in the neuronal cells via the 
enzyme CYP46A1 (24-hydroxylase)(Bjorkhem 2006). The enzyme 24-Hydroxylase is produced 
almost exclusively in the neuron and only a subset of neurons express the enzyme, these include: 
pyramidal cells of the cortex, Purkinje cells of the cerebellum and some neurons of hippocampus 
and thalamus(Lund, Guikeyardo et al. 1999). Expression of 24-hydroxylase is large confined to 
the brain in mouse and humans; there is no evidence to date that of its expression in the 
peripheral nervous system(Russell, Halford et al. 2009). Genetic variation in 24-hydroxylase 
governs the rate each individual converts cholesterol into 24-OHC(Kolsch 2009). The promoter 
region of the CYP46 gene bears all the classical hallmarks of a gene with putative housekeeping 
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functions(Ohyama, Meaney et al. 2006; Brown and Jessup 2009). Therefore, plasma 24-OHC is 
primarily a neuron derived product and its levels in the circulation likely reflect the number of 
metabolically active neuronal cells in the brain able to convert cholesterol to 24-OHC(Leoni 
2009). This is demonstrated patients with brain death, the levels of plasma 24-OHC 
demonstrated a 50% decrease within two hours of brain death(Bretillon and Siden 2000).  
Seminal work by Bjorkhem et al. demonstrates that 24-OHC can cross the blood-brain 
barrier directly by diffusion and is the primary mechanism by which the brain removes excess 
cholesterol(Bjorkhem and Lutjohann 1998; Bjorkhem 2006). The ability of oxysterols to traverse 
the BBB -while cholesterol cannot- results from the addition of the hydroxyl group on the steroid 
side-chain of the cholesterol molecule. Upon contact with the blood-brain barrier, the hydroxyl 
group of the oxysterols induces a reordering of the phospholipid acyl chains within the plasma 
membrane to create a pocket within the plasma membrane which permits the diffusion of the 
oxysterol across the BBB. The diffusion of 24-OHC across the BBB occurs at a rate of 6-7mg/24 
hour(Bjorkhem and Lutjohann 1998). The flux of oxysterols across the BBB appears to be 
concentration dependant. No regulatory factor residing within the BBB has been described yet in 
the literature. 
Once across the BBB, the oxysterols can be extracted by an acceptor such as a circulating 
lipoprotein in the blood. Burkhard et al. determined the distribution of esterified and unesterified 
24-OHC and 27-OHC in lipoprotein sub-fractions(Burkhard, von Eckardstein et al. 2007). They 
found oxysterols, 24-OHC and 27-OHC are carried primary in their esterified form by high 
density lipoproteins (HDL) and low density (LDL) lipoproteins throughout the 
circulation(Burkhard, von Eckardstein et al. 2007). The percent recovery of oxysterols from 
lipoprotein sub-fractions appears to be slightly higher from HDL subfractions than from LDL 
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subfractions(Burkhard, von Eckardstein et al. 2007). Given the lower levels of HDL in the 
circulation, this suggests that oxysterols may be preferentially bound and transported by HDL 
throughout the circulation.  
The elimination of 24-OHC from the circulation is dependent on rate of hepatic 
metabolism by three different species of cytochrome P-450 (CYP7A1, CYP39 and CYP27) 
which conjugate or metabolize oxysterols(Bjorkhem 2006). However, liver disease has not been 
show to affect levels in the circulation(Bretillon and Lutjohann 2000).  
1.2.4 The role of 24-OHC in the brain.  
The production of 24-OHC not only promotes the clearance of excess cholesterol from 
the brain, but may also be involved in signaling the homeostatic mechanisms regulating 
cholesterol production and distribution in the brain. 24-OHC directly suppresses the synthesis of 
cholesterol, via suppression of HMG CoA reductase in the glial cell(Lund, Guikeyardo et al. 
1999). HMG CoA reductase is the rate limiting step in cholesterol synthesis in the body and 
brain(Lund, Guikeyardo et al. 1999). Oxysterols are also believed to be ligands for the nuclear 
receptors found on glial cells(Lehmann, Kliewer et al. 1997). Liver X receptors (LXR) beta and 
alpha regulate sterol transporters ATP-binding cassette A (ABCA1) and G (ABCG1) which 
regulate transport of cholesterol from the glials cells to the neuron. ABCA1 acts by regulating 
ApoE levels and ApoE lipidation which directly affects its ability to carry excess 
cholesterol(Wahrle, Jiang et al. 2004). Studies of combination ABCA1 and ABCG1 knockout 
mice show simultaneous reduction in the rate of cholesterol synthesis and activation of LXR 
signaling(Wang, Yvan-Charvet et al. 2008). When bound to LXR, 24-OHC is believed to 
stimulate ABCA1 to increase the amount of cholesterol carried by ApoE to the neuron.  
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At extremely high levels, 24-OHC is also believed to have direct neurotoxic effects on 
undifferentiated human neuroblastoma cells in vitro(Kolsch and Luthjohann 1999). High levels 
of 24-OHC may induce apoptosis in the surrounding cells which is mediated by the generation of 
oxidative free radicals. Without the presence of antioxidative defense systems, the apoptosis-
oxidative stress cycle continues unabated. These oxidative defense systems such as superoxide 
dismutase are weakened in AD(Richardson 1993). However, studies of 24-OHC kinetic 
demonstrates diffusion of 24-OHC out of the brain is concentration dependent(Bjorkhem 2006). 
Increases in brain concentrations of 24-OHC would be expected to lead to increased diffusion 
across the blood-brain barrier, therein reducing concentrations of 24-OHC in the brain. 
1.2.5 Sources of excess cholesterol in the brain. 
Potential sources of excess cholesterol in the brain may include: excess synthesis from 
glial cells, plasma membrane breakdown, myelin breakdown, and subsequent neuronal cell loss. 
While hypercholesterolemia in the blood can come from de novo and dietary sources, 
hypercholesterolemia in brain is only affected by de novo production and homeostasis(Bjorkhem 
2006). In the brain, cells must produce cholesterol or import the required cholesterol from 
neighboring cells. This process ensures brain cholesterol is derived locally and is highly 
regulated by their oxysterol metabolites. According to the current model of cholesterol 
homeostasis, excessive cholesterol synthesis would stimulate increased production which in turn 
down regulates cholesterol synthesis through LXR signaling(Bjorkhem 2006).  
Moving across the BBB in an opposite flux is the oxysterol 27-hydroxycholesterol (27-
OHC). 27-OHC occurs as an extracellular oxidation of cholesterol. Nearly all the cells in the 
body contain the enzyme 27 hydroxylase (CYP27A1), which is responsible for converting 
 12 
cholesterol into 27-OHC, while macrophages have  the highest levels of CYP27A1. The influx of 
27-OHC into the brain has been found to be about 5mg per 24 hours(Meaney and Heverin 2007). 
The levels in the CSF correspond to levels the circulation, indicating the diffusion of 27-OHC 
from the circulation across the BBB is most likely concentration dependant(Bjorkhem 2006). 
Diffusion of 27-OHC has also been suggested to correspond to the integrity of the BBB. Damage 
to this barrier is believed to result from a higher flux of 27-OHC from the circulation into the 
brain(Leoni and Masterman 2003). 
Disruption of the BBB may consist of gaps within the plasma membrane where systemic 
cholesterol or 27-OHC may enter. In the normal brain, the influx of 27-OHC from the periphery 
into the brain through the BBB is believed to be concentration-dependent(Bjorkhem 2006). With 
increased 27-OHC levels in the circulation as it is found in hypercholesterolemic states, 
disruption of the BBB may increase infiltration of 27-OHC(Leoni and Masterman 2003; Ghribi 
2008). Inside the brain, 27-OHC is metabolized to 7α-hydroxycholesterol (7α-OHC)(Bjorkhem 
2006). Excess 27-OHC in the rabbit brain has been shown to lead to Aβ production and 
deposition(Ghribi 2008). Excess 27-OHC in the brain would not be expected to produce changes 
in 24-OHC production as there is no direct mechanism know to convert 27-OHC to 24-OHC. 
The influx of peripheral cholesterol, through a damaged BBB into the brain, may lead to 
increased 24-OHC production and its diffusion out of the brain. Yet, studies of 24-OHC in stroke 
patients do not show that 24-OHC levels in the plasma are altered by acute BBB 
disruption(Holdenrieder and Lutjohann 2004). The inability to quantify the amount of cholesterol 
or of 27-OHC entering the brain, the relative concentrations of 27-OHC within the brain, and the 
rate at which 27-OHC is metabolized within the brain remain obstacles impeding  further 
examination of this hypothesis in vivo.  
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Myelin breakdown is a common phenomena of aging(Bartzokis 2004). The most 
vulnerable myelin are those produced later in life(Bartzokis 2004). Myelin and its components 
such as cholesterol and myelin proteins are reduced in old age and substantially further reduced 
in mild cognitive impairment (MCI) and dementia(Bartzokis 2009). In vitro evidence 
demonstrates breakdown of the myelin releases fat, iron, and cholesterol into the extracellular 
space and CSF leading to excess cholesterol levels and neuronal death (Figure: Feed Forward 
Loop)(Bartzokis 2004). While all of these instances could lead to dramatically increased 
cholesterol levels in the brain, they will also trigger conversion of cholesterol into 24-OHC 
which is in turn cleared through the BBB into the periphery.  
1.2.6 The role of 24-OHC in amyloidogenesis and Alzheimer’s disease.  
The conversion of cholesterol to 24-OHC may be indirectly neuroprotective, because it 
reduces concentrations of excess cholesterol that lead to increased Aβ production in the 
brain(Lutjohann, Papasotiropoulus et al. 2000). The production of 24-OHC has been shown to be 
an efficient inhibitor of the formation of Aβ in vitro(Brown and Theisler 2004). 24-OHC is 
believed to play a role in the suppression of amyloidogenesis and acts as a stimulator of ApoE-
mediated removal of cholesterol via the CSF(Brown and Jessup 2009). Genetic variation in 24-
hydroxylase is associated with an increased load of Aβ and the early onset of AD (Table 
A1)(Kolsch 2009).  
Alzheimer’s disease is characterized by deposition of beta amyloid (Aβ) in the form of 
neuritic plaques and by neurofibrillary tangles in soluble deposits of hyperphospholated 
tau(Reiss 2005; Blennow and de Leon 2006). In biochemical studies of AD, total tau is used as a 
marker of neurodegeneration, β-amyloid 42 (Aβ42) is used to reflect aggregation and subsequent 
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plaque deposition of β-amyloid, and phosphorylated tau is used as an indicator of 
hyperphosphorylation of tau and formation of neurofibrillary tangles. Among AD and MCI 
patients, CSF levels of 24-OHC are positively and significantly correlated total tau and 
phosphorylated tau in the CSF(Leoni, Shafaati et al. 2006; Solomon, Leoni et al. 2009). The ratio 
of plasma 24-OHC to total cholesterol (24-OHC/Chol) is associated with CSF levels of Aβ42, 
total and phosphorylated tau after controlling for age, sex, ApoE-4 status, and statin 
therapy(Solomon, Leoni et al. 2009). The levels of 24-OHC in the plasma and CSF are highly 
correlated with ApoE levels. In the CSF, the levels of 24-OHC increase additively with the 
number of ApoE-4 alleles. In the plasma, ApoE is an independent predictor of levels of 24-OHC 
and the ratio of 24-OHC/Chol. An in-depth discussion of oxysterols, their links with tau and their 
role in tauopathies is presented by Leoni, Solomon and Kivipelto(Leoni, Solomon et al. 2010).  
1.2.7 Variation in plasma oxysterol levels across the lifespan.  
More than 90% of the 24-OHC in the circulation is of cerebral origin; less than 10% of 
plasma 24-OHC is believed to come from the adrenals, bone marrow, and other 
sources(Bjorkhem 2006; Kolsch 2009). The half-life of 24-OHC in the circulation is 
approximately 12 hours(Bjorkhem and Lutjohann 1998). There appears to be neither diurnal or 
post-prandial variation in levels of 24-OHC. The lack of post-prandial variation confirms that 24-
OHC concentrations are independent of time of nutritional intake(Bjorkhem and Lutjohann 
1998). Variation in plasma levels of 24-OHC appear to vary by age, gender, cholesterol 
concentrations in the brain, metabolism of cholesterol in the gray matter, and genetic variation in 
the family of genes coding for cytochrome P450 enzymes. The levels of 24-OHC tend to be 
higher in women; whereas levels of 27-OHC tend to be higher in men; however neither 
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oxysterols has been shown to vary with the menstrual cycle (Burkhard, von Eckardstein et al. 
2007).  
Variation in plasma concentrations of 24-OHC occurs over the life-span. Concentrations 
are highest in the circulation during the first two decades of life. This is postulated to be a 
consequence of higher production during active myelination relative to a lower degree of hepatic 
metabolism in youth. It has been suggested this is due to a greater head size to liver size ratio in 
youth(Bretillon and Lutjohann 2000). In the absence of neurodegeneration, concentrations of 24-
OHC are relatively stable between the third and seventh decades of life. An age related decline 
appears to be initiated in the sixth and seventh decades of life, which parallels the decline in gray 
matter and total brain volume beginning in the fifth decade of life(Fotenos and Snyder 2005). 
Thelen et al. examined cholesterol, including its precursors and metabolites, in the brains of 
autopsied decedents of various ages that had no history of cognitive or mental disease(Thelen 
and Falkai 2006). The autopsied brains showed that while the amount of total cholesterol was the 
same in young and older participants (<38 versus >38 years of age), the precursors of cholesterol 
were significantly higher in the young participants. The concentration of 24-OHC were 
significantly lower in cerebrospinal fluid of hippocampal sections in older adults compared to 
younger brains(Thelen and Falkai 2006). However the authors did not correlate the levels of 
cholesterol metabolites with the volume or weight of the autopsied brains. 
1.2.8 Challenges to obtaining accurate markers of brain cholesterol metabolism: 
interaction with statins. 
Studies of oxysterols and neurodegenerative disease express plasma levels of 24-OHC in 
three ways: as an absolute value, as a ratio to total cholesterol, and as a ratio to 27-OHC. As 
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outlined above, absolute levels of plasma 24-OHC are regarded as surrogate marker of the 
number of metabolically active neurons located in the gray matter of the brain(Leoni 2009). 
When expressed as a ratio to total cholesterol (24-OHC/Chol), the ratio represents cholesterol 
metabolism to oxysterols in the brain relative to total cholesterol in the circulation (periphery). 
This ratio places potential changes in absolute levels of 24-OHC in the context of changes in 
plasma cholesterol that may be occurring later in life. Longitudinal studies of changes in 
cholesterol levels show that total cholesterol tends to increase with age in young or middle-aged 
adults but decreases in late life(Hershcopf, Elahi et al. 1982; Abbott, Sharp et al. 1997; Ferrara, 
Barrett-Connor et al. 1997; Solomon, Kareholt et al. 2007). In younger participants, potential 
elevations in 24-OHC occurring as a result of neurodegenerative disease may not be evident in 
ratio of 24-OHC to total cholesterol if the levels of total cholesterol remain unaffected.  
The metabolism of cholesterol to oxysterols is likely dependent on cholesterol 
concentrations and affected by statin use. Small studies of patients with normal and elevated 
cholesterol levels have examined the effect of statins on 24-OHC levels in the CSF and 
plasma(Botti and Triscari 1991; Locatelli and Lutjohann 2002; DeKosky 2005; Thelen and 
Laaksonen 2006). The ability of the statin to alter cholesterol synthesis in the brain and the 
subsequent levels of 24-OHC appears to be largely dependent on the ability of the statin to cross 
the BBB. Statins that cannot cross the BBB, appear to depress total plasma cholesterol levels 
without producing reductions in brain cholesterol synthesis or its metabolism to oxysterols; in 
effect, creating a higher ratio of 24-OHC/Chol. Potent lipophilic statins atorvastatin and 
simvastatin can cross the BBB and appear to suppress cholesterol synthesis in the body and brain 
leading to subsequent decreases in the levels of plasma 24-OHC(Locatelli and Lutjohann 2002). 
Conversely, pravastatin is considerably more hydrophilic, and less likely to cross the blood brain 
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barrier. As a result, the ratio of plasma 24-OHC/Chol is expected to be higher patients treated 
with pravastatin compared to patients treated with the BBB penetrating statins, atorvastatin and 
simvastatin. These studies demonstrated that high-dose statin therapy using statins able to 
penetrate the BBB resulted in decreased absolute levels of 24-OHC in the circulation; yet, the 
ratio of 24-OHC to circulating total cholesterol, remained unchanged(Locatelli and Lutjohann 
2002). 
1.3 METHODS OF REVIEW 
1.3.1 Search strategy 
Original articles and reviews were identified by search of Ovid Medline for articles 
published between 1950 and the first week of March 2011. Searches utilized MeSH terms (“24S-
hydroxycholesterol” or “24-hydroxycholesterol”) and (“Brain” or “Cognitive”). The relative 
sensitivity of this search strategy was evaluated by reconditioning the search to include addition 
of the keyword “oxysterol”. The search was repeated using alternative keywords (“oxysterols” 
and (“Brain” or “Cognitive”)) not (“24S-hydroxycholesterol” or “24-hydroxycholesterol”). This 
search provided no additional articles relating 24-OHC levels to neurodegerative disease.  
1.3.2 Selection criteria 
All observational and experimental studies in humans investigating cholesterol 
metabolism in the brain and its relationship to neurodegeneration and cognition were considered. 
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We chose to limit our review to studies evaluating 24S-hydroxycholesterol in human subjects 
and cell lines (n=93). Only original articles involving human subjects were considered for this 
review; we eliminated 17 in vitro and 20 review articles which left 56 suitable articles. These 56 
articles were evaluated and categorized according to the following criteria. Pertinent studies 
included in this review focused on: 1) hydroxycholesterols and neurodegenerative diseases (AD, 
MS, Huntington’s, etc); 2) population based genetics studies of CYP family hydroxylases; 3) 
Extracellular metabolism of cholesterol in the brain; 4) interventions modifying 
hydroxycholesterol synthesis or metabolism. The 26 articles investigating the relationship 
between hydroxycholesterol levels in human subjects with neurodegenerative disease were 
evaluated for the utilization of magnetic resonance imaging modalities. Only five studies were 
found which utilized MRI when evaluating the association between levels of oxysterols and 
neurodegenerative diseases. The selection of articles for review was then limited to just articles 
pertaining to age-related neurodegeneration, including: dementia, Alzheimer’s disease, mild 
cognitive impairment and studies with cognitively normal participants. All review articles were 
assessed for references potentially missed by OvidMEDLINE searches. One reviewer (TMH) 
prepared searches, applied the selection criteria and collected articles relevant to the topic.  
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Figure 2: Flow chart detailing literature review of oxysterols and neurodegenerative diseases 
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1.4 OXYSTEROLS AND NEURODEGENERATIVE DISEASE   
Results of the OVID Medline search produced 19 articles addressing plasma or CSF 
levels of 24-OHC in neurodegenerative diseases [multiple sclerosis (MS) = 3; Alzheimer’s 
disease (AD) = 9; Huntington’s disease = 1; dementia, mild cognitive impairment (MCI), or 
cognitive performance = 4; stroke = 2; and multiple neurodegenerative diseases = 2] Of these 19 
studies (summarized in Tables A1-A4), only five correlate 24-OHC with structural measures of 
brain disease. Three articles utilize MRI to produce volumetric measures of the brain regions for 
comparison between diseased and normal patients(Leoni and Mariotti 2008; Koschak and 
Lutjohann 2009; Solomon, Leoni et al. 2009). Another study, conducted in MS patients, assessed 
the presences of lesions indicative of neurodegenerative disease processes using 
MRI(Karrenbauer and Leoni 2006). However, no study has quantified the extent or severity of 
brain lesions and levels of oxysterols in the brain.  
The use of 24-OHC as a biomarker of neurodegeneration has been investigated in the 
context of various neurodegenerative diseases. Early reports relied strictly on clinical definitions 
of disease processes(Bretillon and Siden 2000; Lutjohann, Papasotiropoulus et al. 2000; 
Papassotiropoulus and Lutjohann 2000; Schonknecht and Lutjohann 2002; Teunissen, Lutjohann 
et al. 2003; Heverin and Bagdanovic 2004; Kolsch and Heun 2004; Leoni, Masterman et al. 
2004; Leoni, Shafaati et al. 2006; Shafaati, Solomon et al. 2007) and did not apply imaging 
modalities for structural confirmation or quantification of disease severity. More recent 
publications have aimed to correlate levels of 24-OHC with structural or biochemical imaging 
techniques of the brain(Leoni and Masterman 2002; Karrenbauer and Leoni 2006; Thelen and 
Falkai 2006; Leoni and Mariotti 2008; Koschak and Lutjohann 2009; Solomon, Leoni et al. 
2009). The latter publications appear to provide direct parallels between oxysterol levels and 
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structural changes in the brain as well as more sensitive staging of disease. A brief summary of 
these studies follows.  
1.4.1 Association with non-dementia neurodegenerative diseases. 
Demyeliating diseases degrade the myelin of the neurons, where the vast majority of 
brain cholesterol is stored; therefore, these diseases provide unique insight into cholesterol 
homeostasis and metabolism during the neurodegenerative disease process (detailed in Table 
A2). Studies of patients with acute demyeliating diseases (Guillian-Barre syndrome and 
inflammatory demyeliating polyradiculoneuropathy) indicate the levels of 24-OHC are increased 
in the patient’s CSF and plasma compared to controls(Leoni, Masterman et al. 2004). The ratio 
of 24-OHC to 27-OHC (24-OHC/ 27-OHC) is also elevated in patients with acute demyelinating 
diseases compared to controls. The literature investigating oxysterol concentrations in patients 
with multiple sclerosis (MS) suggest levels of 24-OHC experience a transitory increase in both 
the plasma and CSF during remitting-relapsing and early stages of disease(Leoni, Masterman et 
al. 2004). Progressive and later stages of disease suggest consistent declines in levels of 24-OHC 
in the circulation(Leoni and Masterman 2002; Leoni, Masterman et al. 2004; Karrenbauer and 
Leoni 2006). Among MS patients, levels of 24-OHC are higher in younger patients and tend to 
decrease with increasing age and disability scores(Leoni, Masterman et al. 2004; Karrenbauer 
and Leoni 2006). Both absolute levels of plasma 24-OHC and the ratio 24-OHC/Chol were 
found to be significantly lower in both primary progressive (PPMS) and relapsing-remitting 
(RRMS) disease states than normal controls(Karrenbauer and Leoni 2006). The current model of 
oxysterols as markers of neurodegenerative disease suggests that plasma and CSF levels depend 
upon stage of disease at which the 24-OHC is measured. Concentrations of plasma 24-OHC may 
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be elevated (early stages), normal (middle stage), or decreased (later and progressive 
stages)(Leoni 2009). This hypothesized trajectory of 24-OHC over the neurodegenerative 
process is used below to evaluate results from cross sectional studies of 24-OHC and dementia. 









1.4.2 Neuroimaging studies of oxysterols and neurodegenerative diseases.  
Magnetic Resonance Imaging (MRI) has recently been utilized in the study of 24-OHC 
and neurodegenerative disease states (Table A3). To date, only one study of dementia and 24-
OHC utilized MRI measures(Solomon, Leoni et al. 2009). MRI has been implemented in studies 
of other neurodegenerative diseases, including MS and Huntington’s disease(Leoni, Masterman 
et al. 2004; Karrenbauer and Leoni 2006; Leoni and Mariotti 2008). Results from these studies 
can provide insight into what we can expect to see from MRI studies of dementia-type lesions. 
Gadolinium-enhanced (Gd) lesions visible on MRI are used in MS to identify primary 
progressive (PPMS) and relapsing-remitting (RRMS) disease states. Gd-positive lesions on MRI 
are believed to indicate areas of active disease, where BBB disruption and ongoing perivascular 
disease may be occurring(Karrenbauer and Leoni 2006). Increased levels of plasma 24-OHC was 
found only in patients with lesion confirmed active disease indicated by Gd-positive MRI scans, 
specifically in PPMS patients(Leoni, Masterman et al. 2004; Karrenbauer and Leoni 2006). The 
presence of hypointense and hyperintense lesions on T1 and T2 weighted MRI have been 
examined in relation to levels of plasma 24-OHC in MS patients. The volume of T2–weighted 
hyperintense lesions is a marker of cumulative disease extent representing a spectrum of events, 
ranging from demyelination and edema to gliosis and axonal loss(Karrenbauer and Leoni 2006). 
In both RRMS and PPMS disease states, decreases in ratio 24-OHC/Chol were associated with 
increases in disease extent as indicated by the volume of T2–weighted hyperintense lesions. In 
RRMS patients alone, the ratio 24-OHC/Chol was positively associated with the volume of T1 
hypointense lesions which are believed to represent axonal loss(Karrenbauer and Leoni 2006). 
These data suggest increases in plasma 24-OHC would be expected in early states of 
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neurodegenerative diseases where demyelination is initiated; whereas decreases in plasma 24-
OHC would be expected in latter stages of disease.  
Plasma levels of 24-OHC were significantly higher in controls than Huntington’s disease 
patients at all stages of the disease. The levels of 24-OHC and 27-OHC paralleled large 
decreases in caudate volumes. Lower levels of plasma 24-OHC were also seen in later more 
advanced stages of disease(Leoni and Mariotti 2008). The correlations between oxysterols and 
caudate volumes were also seen in cognitively normal controls without neurodegenerative 
disease(Koschak and Lutjohann 2009).  
MRI studies of 24-OHC and brain volume show the metabolite of cholesterol is 
differentially associated with fractions of the brain. Segmentation of the brain into CSF, gray 
matter and white matter shows that the ratio of 24-OHC/Chol was positively associated with 
larger grey matter fractions across all subjects with AD, MCI and subjective cognitive 
impairment(Solomon, Leoni et al. 2009). Interestingly, the ratio of 24-OHC/Chol was associated 
with grey matter volume and total brain volume in subjects with subjective cognitive 
impairment, but not in AD and MCI. Due to the high concentration of neurons in the grey matter, 
these findings support the hypothesis that 24-OHC is a marker of the number of metabolically 
active neurons in the brain, but suggest this may only be true for individuals without 
neurodegenerative diseae. Among cognitively normal middle-aged adults, lower plasma levels of 
24-OHC were also associated with smaller brain volumes(Solomon, Leoni et al. 2009) and 
smaller hippocampus(Koschak and Lutjohann 2009). Participants with both high levels of 24-
OHC and 27-OHC had larger hippocampal volumes.(Koschak and Lutjohann 2009) 
Solomon et al. found associations between absolute levels of oxysterols and brain 
volume. They did not find an association between white matter volume and fraction with the 
 25 
ratio of 24-OHC/Chol(Solomon, Leoni et al. 2009). Unfortunately, the investigators did not use 
standard MRI procedures to distinguish normal white matter from white matter hyperintense 
areas visible on MRI. Hyperintense white matter on MRI is indicative of damage to the white 
matter occurring from ischemia and maybe associated with cholesterol metabolism in the brain. 
With the volume of white matter hyperintensities included in the total white matter volume 
interpretations regarding this tissue may be inaccurate. 
1.4.3 Cross-sectional studies of 24-OHC and dementia 
1.4.3.1 Associations with plasma 24-OHC 
Case-control studies have found significant associations between 24-OHC and various 
forms of dementia, specifically severity of disease state; yet, they indicate inconsistencies in the 
direction of association (Table A4). The levels of 24-OHC in the plasma are expected to increase 
in the early stages of the neurodegenerative disease process(Leoni 2009) (Figure 3). Evidence for 
this initial increase in plasma 24-OHC is seen in dementia: AD, vascular dementia (VaD), and 
MCI.(Lutjohann, Papasotiropoulus et al. 2000; Papassotiropoulus and Lutjohann 2000) Three 
studies indicate increased levels of plasma 24-OHC are associated with dementia and MCI. 
These three studies utilize patients referred to memory clinics with memory complaint. Absolute 
levels of plasma 24-OHC were found to be significantly higher in participants with AD, VaD, 
and MCI patients compared to both controls and depressed participants(Lutjohann, 
Papasotiropoulus et al. 2000; Papassotiropoulus and Lutjohann 2000). No significant differences 
were observed between dementia subtypes (AD and VaD) or between depressed participants and 
controls(Lutjohann, Papasotiropoulus et al. 2000). Only one study reported no association 
between absolute plasma levels of 24-OHC in AD compared controls(Schonknecht and 
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Lutjohann 2002). This study found that absolute plasma 24-OHC levels appeared to be higher in 
AD cases compared to controls, but differences were not statistically significant(Schonknecht 
and Lutjohann 2002).  
Plasma levels of 24-OHC correlate with severity of dementia symptoms and genetic risk 
factors for AD. Levels of 24-OHC are negatively correlated with severity of dementia using mini 
mental state exam (MMSE) to assess global cognition scores(Lutjohann, Papasotiropoulus et al. 
2000). Severe AD and the ApoE genotype have been independently associated with both lower 
levels of absolute 24-OHC and a reduced ratio of 24-OHC/Chol in the plasma(Papassotiropoulus 
and Lutjohann 2000). When stratified by early and late stage of AD, levels of 24-OHC were 
found to be slightly higher in the early stages of AD(Papassotiropoulus and Lutjohann 2000). 
Two other cross-sectional studies found that absolute levels of 24-OHC were 
significantly lower in patients with AD compared controls. The first study only included AD 
patients with a long duration of disease. The authors noted that the AD patients were diagnosed 
at least four years before the blood draw and decreases in 24-OHC may represent a progressed 
course of disease and greater disease severity(Bretillon and Siden 2000). The second study 
reporting levels of 24-OHC were lower in cases of AD and MCI compared to controls with 
subjective cognitive impairment(Solomon, Leoni et al. 2009). All participants, including both 
cases and controls, were referred to a hospital memory clinic with memory complaint. Plasma 
levels of 24-OHC and the ratio 24-OHC/Chol were significantly lower in patients with MCI and 
AD compared to controls with subjective cognitive impairment. As in other studies the levels of 
24-OHC were not significantly different between patients with MCI and AD. The authors noted 
that the subjective cognitive impairment patients used as controls presented with concerns of 
some cognitive impairment, but only did not meet a clinical threshold for cognitive impairment. 
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Mean MMSE scores for subjective cognitive impairment, MCI and AD were 29.1, 28.1 and 23.6, 
respectively. The lower levels of 24-OHC corresponded with lower MMSE scores across the 
groups. No direct comparisons to cognitively normal controls could be made from this study. 
1.4.3.2 Associations with ratio 24-OHC to total cholesterol and other oxysterols. 
While absolute levels of 24-OHC appear to increase in the early stages of dementia, the 
ratio of 24-OHC to total circulating cholesterol may decrease or remain unchanged in AD, MCI 
and VaD. The ratio of 24-OHC to total cholesterol is significantly lower in AD, VaD and MCI 
compared to controls(Kolsch and Heun 2004). The ratio of plasma 24-OHC/Chol correlates 
negatively with severity of disease and is associated with ApoE-4, Aβ42 and tau related 
proteins(Lutjohann, Papasotiropoulus et al. 2000; Papassotiropoulus and Lutjohann 2000; 
Solomon, Leoni et al. 2009). It appears that the ratio of 24-OHC/Chol may only be elevated in 
mild versus severe states of the disease(Papassotiropoulus and Lutjohann 2000). A paper by 
Teunissen et al  reported the ratio of 24-OHC to total cholesterol was not significantly different  
patients with various neurological disease compared to controls(Teunissen and De Vente 2003; 
Teunissen, Lutjohann et al. 2003). The author’s combination of clinical syndromes (Alzheimer’s 
disease, obsessive compulsive disorder, and Parkinson’s disease) into a comprehensive 
‘neurological patients’ group produced no significant differences in the ratio of 24-OHC to total 
cholesterol in cases compared to controls(Teunissen, Lutjohann et al. 2003). The investigators 
noted, but didn’t show, that results from the analysis of variance test indicated that the ratio of 
24-OHC to total cholesterol differed significantly across the groups.  
One study of oxysterols and AD investigated oxysterol formation in the brain relative to 
oxysterol formation in periphery as a ratio of 24-OHC to 27-OHC. This study showed the ratios 
of both 24-OHC/Chol and 27-OHC/Chol appear to be lower in patients with AD, VaD and MCI 
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compared to controls. Interestingly, the plasma ratio of 24-OHC/27-OHC was significantly 
elevated in the AD, VaD and MCI participants compared to controls(Kolsch and Heun 2004). 
These findings suggest higher cholesterol metabolism to oxysterols occurs in the brain versus the 
periphery early in the dementia process; furthermore these results show higher cholesterol 
metabolism in the brain versus the periphery in patients with mild cognitive impairment 
compared to cognitively normal controls(Kolsch and Heun 2004).  
1.4.3.3 Associations with 24-OHC in the cerebrospinal fluid. 
Measurements of 24-OHC in the CSF, taken from spinal fluid, are more consistent than 
those measured from the plasma. 24-OHC in the CSF is believed to indicate active and acute 
neurodegeneration(Leoni and Masterman 2003). CSF levels of 24-OHC are significantly 
increased in MCI and AD patients, specifically in the frontal cortex of AD 
patients(Papassotiropoulus and Lutjohann 2002; Heverin and Bagdanovic 2004; Shafaati, 
Solomon et al. 2007). CSF concentrations of 24-OHC are significantly, yet slightly, elevated in 
MCI patients compared to controls(Papassotiropoulus and Lutjohann 2002). In participants with 
normal cholesterol levels, CSF 24-OHC levels is significantly higher in AD patients compared to 
controls(Schonknecht and Lutjohann 2002). The number of ApoE-4 alleles additively increased 
the levels of 24-OHC in the CSF(Papassotiropoulus and Lutjohann 2002); however levels of 24-
OHC were not correlated to beta amyloid and tau protein in the CSF(Shafaati, Solomon et al. 
2007). In autopsied brain tissue samples, the ratio of 24-OHC/27-OHC in the CSF is elevated in 
AD patients compared to controls. Despite having autopsied brain samples, the authors did not 
control for brain volume or weight and no designation was made for the amount of healthy or 
diseased brain tissue(Heverin and Bagdanovic 2004). 
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1.4.4 Longitudinal studies of 24-OHC with cognitive decline 
Cognitive decline can be viewed as the overarching clinical manifestation of the dementia 
process. In dementia patients, plasma 24-OHC is associated with global cognitive performance 
(MMSE) often used as a marker of disease severity. Table A5 details the two studies assessing 
the relationship between 24-OHC and longitudinal cognitive decline(Teunissen and De Vente 
2003). The results from these two studies are either incomplete or insufficient (due to small 
sample size) when taken alone, but complimentary when examined together. The first study 
attempted to determine if cholesterol and oxysterols concentrations are associated with cognitive 
performance in the healthy aging population over six years of follow-up using a relatively small 
sample size (n=65 participants at both baseline and follow-up)(Teunissen and De Vente 2003). 
Absolute levels of both 24-OHC and 27-OHC are correlated with individual cross-sectional 
cognitive performance at baseline and follow-up. Longitudinally, only the ratio of 24-OHC/Chol 
was related to significantly slower speed of processing at follow-up and not other cognitive tests. 
This study suffered from many limitations, including: the small number of participants had both 
baseline and follow-up measures of cognition; little variation was seen over 6 years in the 
cognitive scores of participants; also the failure to adjust for, or exclude, individuals that were 
currently taking statins during the observation period.  
A recent prospective study collected longitudinal cognitive testing over 6 years of follow-
up in over 1000 participants, 65 and older, who were not taking statins and cognitively normal at 
baseline(van den Kommer, Dik et al. 2009). The authors found that low total cholesterol in 
participants 65 years and older is an independent predictor of cognitive declines over six years. 
The ratios of 24-OHC/Chol and 27-OHC/Chol were significantly lower in ApoE-4 carriers. 
ApoE-4 status, the ratio of 24-OHC/Chol and the ratio of 27-OHC/Chol showed no association 
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to cognitive decline over six years. Only the ratio 27-OHC/Chol was inversely associated with 
performance on MMSE and immediate recall tests in ApoE-4 carriers. While the association 
between the ratio 24-OHC/Chol and cognitive performance over six years was not statistically 
significant, an interaction between the ratio of 24-OHC/Chol and the ApoE-4 allele suggested 
that ApoE-4 is a potential moderator of association between ratio 24-OHC/Chol and speed of 
processing. Unfortunately, the authors did not report the cross-sectional associations between 
cognition and 24-OHC or 27-OHC at baseline or follow-up. These results support the hypothesis 
that decreased serum cholesterol in late-life may reflect ongoing pathological processes and may 
represent a risk marker for cognitive impairment and dementia.  
In summary, 24-OHC is believed to be a marker of the number of metabolically active 
neurons in the brain able to convert excess cholesterol to 24-OHC and has been used extensively 
as a biomarker in studies of neurodegenerative  diseases. However, its associations with age-
related cognitive impairment and dementia have been inconsistent, partially due to factors 
including: study design; point of the disease process at which 24-OHC is assessed; and how it is 
expressed as an absolute value or ratio compared to total cholesterol levels. Studies of oxysterols 
show 24-OHC is higher in AD, MCI and VaD early in the disease process when compared to 
cognitively normal controls. The levels of plasma 24-OHC correlate with ApoE genotype, scores 
of global cognition and severity of disease.  
1.5 DISCUSSION OF RESULTS FROM SYSTEMATIC REVIEW  
The presence of the blood brain barrier makes cholesterol in the circulation a distant and 
poor marker of cholesterol concentrations in the brain. The metabolism of cholesterol to 24-OHC 
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accounts for 99% of the cholesterol eliminated from the brain and makes 24-OHC a more 
proximate marker of cholesterol homeostasis in the brain. Excess cholesterol in the brain can 
come from either the excess synthesis of cholesterol or the breakdown of the cholesterol-rich 
myelin during neuronal death. Both sources of excess cholesterol in the brain will increase the 
elimination of cholesterol as 24-OHC and levels of 24-OHC in the blood. The conversion of 
excess cholesterol to 24-OHC occurs in the neuron; therefore it is also considered a marker of 
number of metabolically active neurons in the brain. Previous studies demonstrate that 24-OHC 
is associated with the diagnosis and severity of dementia and other neurodegenerative diseases. 
The concentration of 24-OHC in relationship with dementia may depend upon the stage of 
disease at which the 24-OHC is measured. Specifically, we propose (in Figure 3) the 
concentrations of plasma 24-OHC may be elevated (in the early stages of dementia, due to 
myelin loss), normal (in middle stages, an equilibrium may be reached through increased 
conversion of cholesterol to oxysterols and subsequent elimination), or decreased (in later and 
progressive stages, when the neuronal loss that accompanies the neurodegenerative process 
causes lower concentrations of CYP46, the enzyme that converts cholesterol to 24-OHC). Early 
stage myelin breakdown is expected to increase levels of free cholesterol in the brain and its 
primary metabolite, 24-OHC in the blood. A progressive course of disease -characterized by 
pervasive synaptic and neuronal loss leading to progressive atrophy- will result in increases in 
initial increases in 24-OHC. This process will continue until the number of metabolically active 
neurons in the brain cannot keep pace with excess cholesterol levels in the brain resulting in 
declines in 24-OHC levels in step with severity.  
When measured in the CSF, 24-OHC is a marker of active neurodegenerative disease. 
Increased levels of 24-OHC in the CSF are believed to indicative of active neurogenerative 
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disease(Leoni 2009). CSF levels of 24-OHC have been shown to be elevated in AD and MCI 
patients. These associations appear to be independent of circulating cholesterol levels. Evidence 
from MS supports this assumption(Leoni and Masterman 2002; Karrenbauer and Leoni 2006).  
When measured in the plasma, the associations between dementia and 24-OHC appear to 
be less consistent. However, these inconsistencies likely result from two design issues: the stage 
of the disease process (severity) at which 24-OHC is assessed; and whether levels of 24-OHC are 
expressed as an absolute measure or as a ratio of 24-OHC to total cholesterol. The levels of 
absolute 24-OHC are expected to increase in the early stages of the neurodegenerative disease 
process, and decline with severity of disease. Evidence for this increase is seen not just in MCI, 
but also in early stages of AD and VaD. With increased duration and severity of disease, both the 
absolute levels of 24-OHC and the ratio of 24-OHC/Chol appear to decline. Studies showing a 
lower ratio of 24-OHC/Chol in participants with neurodegerative disease also demonstrate that 
total cholesterol levels do not differ between controls and cases of AD and MCI(Solomon, Leoni 
et al. 2009). Studies reporting no association or lower levels of plasma 24-OHC in AD patients 
compared to controls fail to account for the severity or stage of disease. One study reporting 
lower levels of plasma 24-OHC in AD patients compared to controls noted that the AD patients 
all were diagnosed with disease a minimum of 4 years before blood draw. As demonstrated by 
the increase ratio of 24-OHC to 27-OHC seen in dementia patients, elevations in 24-OHC appear 
to occur relative to 27-OHC levels.  
Plasma levels of 24-OHC lacks the specificity to differentiate AD patients and other 
neurodegenerative diseases, such as Parkinson disease(Teunissen, Lutjohann et al. 2003). 
However, it appears 24-OHC is unable to differentiate dementia patients (AD and VaD) from 
MCI patients. This suggests that the changes in cholesterol metabolism in the brain occur long 
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before cognitive impairment becomes severe. The mechanism is responsible for the elevation in 
24-OHC in the early stages of the neurodegenerative disease process remains uncertain.  
Cholesterol levels and statins clearly modulate APP processing in vitro and in vivo(Reid, 
Urano et al. 2007). Statin trials (using statins known to cross the BBB) have been unable to 
demonstrate a reduction in dementia risk calls into question the hypothesis that cholesterol 
synthesis alone is involved in the Alzheimer’s disease pathology. Studying factors regulating 
cholesterol homeostasis in the brain (both synthesis and elimination) are essential to 
understanding hypercholesterolemia in the brain. Early in the disease process, excess cholesterol 
in the brain could lead to both increases in Aβ deposition in the brain, and increases in 24-OHC. 
Aβ deposition can now be visualized in vivo by positron emission tomography using the 
Pittsburgh compound B (PiB-PET). States of excess cholesterol in the brain would be expected 
to show positive correlations between 24-OHC and PiB-PET. 
Studies involving 24-OHC and dementia fail to consider the underlying pathology which 
could account for states of excess brain cholesterol in dementia studies, or whether 24-OHC is a 
plausible marker of cholesterol metabolism and dementia pathology. More importantly, studies 
of 24-OHC and dementia appear to overlook the importance of myelin breakdown: 1) as a 
potential source of excess cholesterol in the brain; 2) as a potential source of increased levels of 
24-OHC in the circulation; and 3) as a potential initiating event in the development of 
neurodegeneration and dementia. In vivo tools exist to quantitatively measure the integrity of the 
myelin and white matter of the brain; however, these tools remain underappreciated in the 
oxysterol literature. The inconsistencies of the initial associations between plasma 24-OHC and 
AD underscore the importance of examining 24-OHC in the context of the structural 
abnormalities involved in the dementia process. These processes occur at different points in the 
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dementing process or may occur in isolation. Understanding these relationships show 24-OHC 
either a marker neuronal activity or a sensitive, early marker of initiating events in the pathology 
of dementia. 
Long standing and recent advances in Magnetic Resonance Imaging (MRI) have enabled 
visualization of abnormal white matter as well as quantitative means to evaluate the integrity of 
the brain’s white matter. MRI sequences needed to visualize and quantify structural changes in 
the brain of vascular nature are readily available. Standard sequences (T1, T2, PD and FLAIR) 
provide insight into hypo- and hyper-intense lesions within the white matter. The techniques 
exist to quantify the integrity of the white matter (healthy white matter fraction), the extent of 
white matter disease (white matter lesion grade or volume) and the relative health of the brain 
tissue. Studies have yet to investigate the relationship between these lesions, commonly seen in 
cerebrovascular disease and dementia, and their relationship to oxysterols concentrations. In 
addition, Magnetic Transfer Imaging (MTI) and Diffusion Tensor Imaging (DTI) techniques can 
provide measures of white matter integrity and measures of axonal diffusion, respectively.  
Volumetric MRI indicates plasma 24-OHC was significantly associated with total brain 
volume and volume of the grey matter in participants with subjective and clinical cognitive 
impairment(Solomon, Leoni et al. 2009). The association between 24-OHC and grey matter 
volume supports the theory 24-OHC as a marker of the number of metabolically active neurons 
in the brain. Unfortunately this study did not evaluate the integrity of the white matter measured. 
The report that 24-OHC was not significantly associated with white matter volume is not 
surprising because early white matter disease (visible as hyperintensities on MRI) may not 
necessarily result in loss of white matter volume. What was measured in this study was total 
white matter volume, which contains two compartments: volume of diseased white matter 
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(undergoing myelin breakdown) and volume of healthy white matter (white matter integrity). 
Understanding the relationship between 24-OHC and white matter integrity may be essential to 
our understanding of Alzheimer’s disease and its initiating events. Volumetric MRI can be used 
to calculate brain volume and assess areas of relative atrophy. What has been reported regarding 
the association between 24-OHC and brain volume is potentially incorrect if studies do not 
account for active demyelination of the white matter.  
Plasma and CSF levels of 24-OHC have been associated with vascular dementia, brain 
volume, and cognitive performance at the cross-sectional level. With respect to AD 
development, the temporality of changes in oxysterols and onset of dementia has not been 
assessed. Associations between 24-OHC and ‘pre-AD’ states (e.g. MCI, and cognitive decline) 
suggest that higher levels of 24-OHC are related to changes earlier stages of dementia process. 
No studies have directly evaluated relationship between 24-OHC or 27-OHC and direct markers 
of the dementia process. The myelin model of AD development suggests that white matter 
disease could be the preceding events to AD development. MRI sequences can visualize and 
quantify structural changes in the brain; however, no study has investigated these lesions in 
relation to oxysterols. MRI can be used to assess the integrity of the white matter and extent of 
white matter disease in vivo. A comprehensive study utilizing longitudinal measures of 
cholesterol measures (total cholesterol, 27-OHC and 24-OHC) and longitudinal measures of 
cognitive performance and assessment of white matter integrity using MRI is greatly needed.  
Epidemiological and in vivo studies show that 24-OHC is a direct and non-invasive 
marker of cholesterol homeostasis in the brain, and 24-OHC may be associated with AD. 
However, the associations between 24-OHC to amyloid deposition remains unknown. This 
association can be examined by visualizing amyloid deposition in vivo using PiB-PET. 
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Understanding this association in participants with AD and in the cognitively normal is essential 
to our understanding of the AD process and the validity of 24-OHC as a marker of AD. Studies 
that examine dementia: evaluate controls in the same manner as cases; provide cognitive 
comprehensive examinations as well as neuropsychological examinations to all participants; 
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Background: Cholesterol is believed to play a role in the development of Alzheimer’s disease 
(AD). Although total cholesterol levels have been associated with incident dementia in elderly 
subjects, the cholesterol in the blood has little relevance to cholesterol in the brain due to its 
inability to cross the blood brain barrier (BBB). However, two enzymatically formed metabolites 
of cholesterol, 24S-hydroxycholesterol (24-OHC, a brain-derived oxysterol) and 27-
hydroxycholesterol (27-OHC, a peripherally derived oxysterol), cross the BBB and have been 
associated with AD. We investigated whether 24-OHC is associated with markers of 
cerebrovascular disease prior to the onset of cognitive impairment.  
Methods: We quantified oxysterols, 24-OHC and 27-OHC, on a sub-set (n=105) of participants 
from the Pittsburgh Cardiovascular Health Study Cognition Study (CHS-CS) who remained 
cognitively normal (CN) in 1998-9 and had MRI in 1992 and 1998, blood drawn in 2002, and 
annual cognitive exams between 1998 and 2010. Diagnosis of incident AD and mild cognitive 
impairment (MCI) between 1998 and 2010 was made by consensus conference.  
Results: Participants included in this sub-study had a mean age of 80±4 years in 2002 and were 
followed for 7.4 years. Forty-three participants developed AD and 36 MCI. In participants with 
incident cognitive impairment (AD and MCI) compared to CN: plasma levels of 24-OHC were 
higher (CN=39, MCI=43, AD=43, p=0.05); while the levels 27-OHC tended to be lower 
(CN=268, MCI=235, AD=227, p=0.18); thus, making the ratio of 24-OHC to 27-OHC (24-
OHC/27-OHC) significantly higher (CN=0.17, MCI=0.19, AD=0.20, p=0.02). Higher levels of 
24-OHC, but not 24-OHC/27-OHC, were associated with higher white matter hyperintensity 
(WMH) grade (WMH<2=39 vs. WMH≥2=45, p=0.01) and the presence of MRI-defined infarcts 
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(no infarcts=41 vs. infarcts=47, p=0.05) at prior MRI in 1997-8. Plasma 24-OHC and 24-
OHC/27-OHC were not associated with ApoE-4 status. 
Conclusions: The higher ratio of 24-OHC/27-OHC, suggesting increased oxidative cholesterol 
metabolism in the brain versus the periphery, was associated with incident cognitive impairment 
over 8 years of follow-up. 24-OHC was also significantly higher in participants with higher 
WMH grade and infarcts at least four years before the onset of cognitive impairment. 
Measurement of oxysterols may provide information about cholesterol metabolism and brain 




High total cholesterol levels are associated with cardiovascular and cerebrovascular 
disease(Goldstein, Bushnell et al. 2011), and with incident dementia and mild cognitive 
impairment (MCI)(Kivipelto, Helkala et al. 2001) in elderly subjects, suggesting that brain 
cholesterol plays a role in the development of Alzheimer’s disease (AD). The vast majority of 
cholesterol in the brain resides in the myelin (70-80%) where is provides insulation to the axon 
essential to signaling between neurons(Snipes and Suter 1997). In vitro evidence suggests that 
excess cholesterol in the plasma membrane of brain cells initiates: cleavage of amyloid precursor 
protein by β-secretase, production of beta amyloid (Aβ), and Aβ deposition as 
plaques(Fassbender and Stoick 2002). However, cholesterol levels in the blood have little 
relevance to cholesterol levels in the brain because cholesterol cannot cross the blood brain 
barrier (BBB) (Reiss 2005).  
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Two enzymatically formed metabolites of cholesterol, 24S-hydroxycholesterol (24-OHC, 
a brain-derived metabolite) and 27-hydroxycholesterol (27-OHC, a peripherally derived 
metabolite), can cross the BBB directly by diffusion and can be measured in the blood(Bjorkhem 
2006). 24-OHC is the primary metabolite of cholesterol in the brain and is associated with both 
risk of AD and brain volume(Leoni 2009; Solomon, Leoni et al. 2009). However, associations 
between plasma 24-OHC levels and AD have been inconsistent in cross-sectional analyses(Leoni 
2009). Little is known about the relationship between 24-OHC and structural changes in the 
brain prior to the onset of cognitive impairment. We investigated whether brain-derived, 24-
OHC is associated incident cognitive impairment and with markers of cerebrovascular disease 
prior to the onset of cognitive impairment. Specifically we: determined the reproducibility and 
reliability of plasma oxysterol measurements from stored blood samples; quantified the 
retrospective associations between plasma oxysterol levels and MRI markers of cerebrovascular 
disease and markers of AD; and evaluated the prospective associations between oxysterols and 
incident cognitive impairment.  
2.2 METHODS 
Subjects  
The Pittsburgh Cardiovascular Health Study Cognition Study (CHS-CS) is a sub-study of 
the Cardiovascular Health Study. Eligibility for the CHS-CS (n=532) participants included: MRI 
of the brain and detailed cognitive exam in 1992-93 and a second MRI or detailed cognitive 
exam in 1998-99. Participants were non-demented in 1998 and followed to 2010 with repeat 
cognitive tests to determine the incidence of dementia and mild cognitive impairment (MCI). For 
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the purpose of this study we selected 105 participants from this CHS-CS who were cognitively 
normal in 1998-99 and 2002, had blood drawn in 2002, and had repeat cognitive exams between 
2002 and 2010.  
 
Assay of oxysterols and cholesterol  
The general blood collection and laboratory methods have been previously published 
(Cushman, Cornell et al. 1995). Single tubes for analysis of total plasma lipids and oxysterols 
were thawed once for each assay. Oxysterols (24S-hydroxycholesterol and 27-
hydroxycholesterol) were assayed by isotope dilution using gas chromatography/mass 
spectroscopy (GC/MS)(Dzeletovic and Breuer 1995). Reproducibility and reliability of oxysterol 
measures were determined using a random selection of 14 samples with assay repeated one 
month apart. We obtained direct measures of lipids (total cholesterol, HDLc, triglycerides) and 
calculated LDLc from the same sample tubes collected in 2002.  
 
Diagnosis of cognitive impairment 
The diagnosis of dementia and MCI was based on cognitive and neuropsychological 
batteries (Lopez, Kuller et al. 2007). The diagnosis of dementia was based on a deficit in 
performance in two or more cognitive domains that was of sufficient severity to affect the 
subject’s activities of daily living and on history of normal intellectual function before onset of 
cognitive abnormalities(Lopez, Kuller et al. 2007). An adjudication committee classified 




ApoE genotyping  
ApoE allele 4 (ApoE-4) carrier status was determined in CHS using genotyping procedures 
previously described(Kuller, Shemanski et al. 1998). 
 
Brain Imaging  
Because not all participants had an MRI of the brain in 2002-03, we examined the 
relationship between oxysterols levels in 2002 and MRI measures in 1997-98. All MRI data 
acquired in 1998-1999 using a 1.5-T GE Signa system (LX version; Milwaukee, WI) were 
previously published(Yue, Arnold et al. 1997). White matter hyperintensity (WMH) grade was 
estimated as the total extent of periventricular and subcortical white matter signal abnormality on 
spin-density-weighted axial images that successively increased from no or barely detectable 
hyperintensities (grades 0 and 1, respectively) to almost all white matter involved (grade 9)(Yue, 
Arnold et al. 1997). Abnormalities interpreted as representing areas of large-vessel cerebral 
infarction or small-vessel lacunar infarction were coded separately in the database as infarct-like 
lesions(Kuller, Longstreth et al. 2004). The degree of ventricular enlargement was also assessed 
on a 10-point scale from 0 to 9, according to an atlas of predefined visual standards(Yue, Arnold 
et al. 1997). 
 
Statistical Analysis 
Reproducibility and reliability of repeated oxysterol measures were estimated by 
calculating the intra-class correlation coefficients (SAS, PROC VARCOMP) and evaluated 
outliers and systematic bias using scatter plots and Bland-Altman plots. Both 24-OHC and 27-
OHC were found to have approximately normal distributions. Differences in potential covariates 
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between the analytic subset (n=105) and the eligible CHS-CS participants (n=524) were 
evaluated by t-tests and χ2 tests.  
The associations between oxysterols, potential covariates and prior MRI measures were 
estimated using multivariable linear regression. The prospective associations between oxysterols 
and incident cognitive impairment were estimated using multinomial logistic regression. 
Findings from logistic models were confirmed considering time to cognitive impairment by 
quartiles of oxysterols concentrations using log-rank tests, Kaplan-Meier curves and Cox 
proportional hazards models. Models were first estimated adjusting only for age and then 
controlling for age, gender and total cholesterol levels in 2002. In time to event models, the 
proportional hazards assumptions were met for oxysterols predictors of time to cognitive 
impairment; however the inclusion of age did not meet proportional hazards assumptions. All 
analyses were conducted using SAS v9.2 and level of statistical significance was set at p<0.05.   
2.3 RESULTS 
Participants included in this sub-study were to be younger and more educated than the 
rest of the participants in CHS-CS (Table 1). The mean age of this sub-set was 80±4 years in 
2002, 55% were women (58 of 105), and 66% (68 of 105) had greater than high school 
education. All (n=105) participants underwent MRI-1 in 1992-93 and 93 had a second MRI in 
1998-99. No significant differences were observed between this sample and the CHS-CS 
participants (n=532) with regard to gender, race, cholesterol levels in 1992, and cardiovascular 
disease. Nineteen percent of the participants were ApoE-4 carriers. Mean cholesterols measures 
(mg/dL) measured in 2002 were: 187 for total cholesterol, 49 for HDLc, and 109 for LDLc. 
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Table 1: Characteristics of analytic subset in 2002 
    CHS-CS cohort Analytic sample   
    (n=524) (n=105) p-value 
Age, mean, std    82.1 3.9 80.2 3.8 <0.001 
Women, n, % 265 62 58 55 0.199 
Education >12 years, n, % 228 53 68 65 0.035 
White, n, %  335 79 80 76 0.764 
ApoE-4 allele*, n, % 87 23 19 20 0.499 
Coronary Heart Disease, n, % 79 19 16 16 0.435 
Cholesterol in 1992 (mg/dL), mean, std 213.0 38.8 214.9 38.5 0.683 
Cholesterol in 2002 (mg/dL), mean, std 
     
 
Total -- -- 186.7 40.0 
 
 
HDLc -- -- 49.2 13.0 
 
 
LDLc -- -- 109.3 32.0 
 
 
Triglycerides -- -- 140.9 66.6 
 Oxysterols in 2002 (ng/mL), mean, std    
   
 
24-OHC -- -- 42.2 11.8 
 
 
ratio 24/27 -- -- 0.2 0.1 
 
 
27-OHC -- -- 238 81.1 
               
*ApoE genotyped on n=382 in CHS-CS and n=97 in analytic subset. 
    
 
 
Measures of plasma oxysterols obtained from 105 samples averaged 42 ng/mL for 24-
OHC and 238 ng/mL for 27-OHC. Measures of 24-OHC and 27-OHC were highly reproducible 
and reliable, when repeated one month apart, with intra-class correlation coefficients of 0.85 and 
0.73, respectively. Evaluation of Bland-Altman plots of repeated measures for each oxysterol 
indicated no relative bias or outliers between sample preparations.  
Higher plasma levels of 24-OHC in 2002 were associated with female gender, and with 
higher cognitive scores on digit-symbol substitution test, higher total cholesterol and higher 
LDLc as measured at study entry in 1992-93 (data not shown). The use of lipid lowering 
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medications (at year 9) resulted in significantly lower levels of plasma 24-OHC (p=0.028) but 
not of 27-OHC or MRI outcomes. An inverse correlation between 27-OHC and age was present 
(r=0.19, p=0.05); however no correlation between 24-OHC and age was indicated (r=0.05 
p=0.39). Oxysterols 24-OHC and 27-OHC were highly correlated with concurrent measures 
(2002) of total cholesterol (r>0.25, p<0.01, both) and LDLc (r>0.25, p<0.01, both) but not with 
HDLc levels (r<0.04, p>0.45, both). Education, race, MMSE, and white matter grade at MRI-1 
(1992-93) were not associated with plasma oxysterols (data not shown). 
Higher levels of 24-OHC in 2002 were significantly associated with higher WMH grade 
(WMH<2=39 vs. WMH≥2=45, p=0.01) and the presence of MRI-defined infarcts (no 
infarcts=41 vs. infarcts=47, p=0.05) at MRI-2 in 1997-1998. Associations between 24-OHC and 
WMH grade were independent of age, gender, and total cholesterol levels in 2002(Table 2). 
Additional adjustment for dementia diagnosis over the study period (1998-2010) and statin use 
had little effect on these associations (p=0.04, data not shown). The inclusion of ventricle size 
and ApoE-4 carrier status produced mild attenuation of these relationships (p=0.06, data not 
shown). The 17 participants with MRI-defined brain infarcts at MRI-2 also had significantly 
elevated 24-OHC and 27-OHC in 2002 (Table 2). These associations were minimally modified 
by adjustment for age, gender, cholesterol and additional adjustment for dementia diagnosis over 
the observation period (1999-2010) and size of the ventricles on MRI-2 (data not shown). Plasma 
24-OHC and 27-OHC were not associated with age-related size of the ventricles on MRI or 
ApoE-4 carrier status (Table 2). 
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Table 2: The associations between plasma oxysterol levels and MRI measures of cerebrovascular disease and AD 
       Oxysterol measured in 2002 (ng/mL) 
   
24S-hydroxycholesterol 27-hydroxycholesterol Ratio 24-OHC/27-OHC 
    n  mean std p-value mean std p-value mean std p-value 
MRI-defined markers of cerebrovascular disease (1998) 
      White Matter Grade, n=93  
          
 
<2 41 39.2 10.8 0.014 225.7 74.2 0.053 0.18 0.05 0.907 
 





 Infarcts, n=93 
          
 
No infarcts 76 41.3 11.3 0.059 232.6 70.5 0.013 0.18 0.05 0.463 
 






            Markers of AD (1998) 
         Size of ventricles on MRI, 
n=93 
          
 
<5 82 42.3 11.6 0.363 245.7 78.5 0.936 0.18 0.05 0.255 
 





 ApoE genotyping, n=105 
          
 
e4 - 86 42.7 11.8 0.664 244.3 80.2 0.179 0.18 0.05 0.393 
  e4 + 19 41.6 11.3   219.6 60.9   0.19 0.04   
*p-values adjusted for age, gender and total cholesterol levels in 2002. 
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Between 1998 and 2001, 6 participants (5.7% of the analytic sample) were diagnosed 
with prevalent AD (prior to blood draw in 2002) and were excluded from analyses of incident 
cognitive impairment. During mean follow-up of 7.4 years, 37 participants went on to develop 
incident AD and 36 developed MCI between 2002 and 2010. Only 26 participants remained 
cognitively normal over the entire observation period (1998-2010) and had a mean age of 85.6 
years in 2010. Incident AD was associated with older age, gender and greater ventricular grade 
in 1998-99. Incident MCI (n=36, between 2002-2010) was associated with age and having an 
increased WMH grade in 1992-93, but not WMH grade in 1998-99. Neither 24-OHC nor 27-
OHC was significantly associated with prevalent AD, incident MCI and incident AD when 
considered as separate groups compared to normal controls. When combined as a single group as 
incident cognitive impairment, participants developing incident CI had significantly higher levels 
24-OHC (CN=0.39, MCI=0.43, iAD=0.43, p=0.05), slightly lower levels of 27-OHC (CN=268, 
MCI=234, iAD=227, p=0.18) and a significantly higher ratio of 24-OHC to 27-OHC (CN=0.17, 
MCI=0.19, iAD=0.19, p=0.02). The trend in the ratio of 24-OHC to 27-OHC was also significant 
across these three groups (cognitively normal, MCI and AD, p=0.021) (Table 3).  
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Table 3: Oxysterols as predictors of incident cognitive impairment (n=99) 
 






adjusted    




(1998-2010) (2002-2010) (2002-2010) (AD + MCI) 
  
(n=26) (n=36) (n=37) 
age-
adjusted    
p-value 
Model 2    
p-value     mean std Mean std mean Std 
24-OHC  ng/mL 39.1 10.5 43.4 13.0 43.3 11.5 0.153 0.054 0.155 
27-OHC  ng/mL 268.7 114.7 234.9 66.1 227.4 63.8 0.821 0.185 0.478 
24-OHC/27-OHC 0.17 0.05 0.19 0.06 0.19 0.05 0.021 0.019 0.159 
*Prevalent cases of dementia in 2002 (n=6) excluded from analysis of incident cognitive impairment (CI). 
 Model 2 - p-value adjusted for age, gender and total cholesterol.
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Results from time to event analyses (Figure 4) confirmed results from logistic regression 
models. Quartiles of 24-OHC were marginally associated with time to cognitive impairment over 
follow-up period (log-rank test, p=0.065). The lowest quartile of plasma 24-OHC was 
significantly less likely to develop dementia over the follow-up period in unadjusted proportional 
hazards models [HR(95%CI) = 0.52(0.27-0.98)]. This difference in survival time held after 
adjustment for age; however, inclusion of age caused to model to fail proportional hazards 
assumptions. Quartiles of 27-OHC were not associated with differential time to cognitive 
impairment (log-rank test, p=0.876). The ratio of 24-OHC/27-OHC was marginally associated 
with time to cognitive impairment in log-rank tests (log-rank test, p=0.055); however, individual 
quartiles were not significantly different in unadjusted proportional hazards models. 
 










Measures of oxysterols were highly reliable and reproducible when measured in stored 
plasma. Levels of 24-OHC were significantly higher in 2002 among participants with large 
vessel infarcts and high white matter grade at MRI-2 (1998-99), at least 4 years prior to the onset 
of cognitive impairment. Furthermore, higher levels of 24-OHC in 2002 were associated with the 
development of incident cognitive impairment over 8 years of follow-up. Higher concentrations 
of circulating levels of 24-OHC also occurred relative to levels of 27-OHC in participant who 
went onto develop incident CI, resulting in a significantly higher ratio of 24-OHC/ 27-OHC, 
indicating a higher production of oxysterols in the brain versus the periphery. This association 
was independent of age, gender and total cholesterol measured in 2002. These results suggest 
increased cholesterol metabolism to oxysterols occurs in the brain versus the periphery in 
participants who went on to develop incident CI. Interestingly, levels of both plasma 24-OHC 
and 27-OHC were higher in participants with cerebrovascular disease on MRI prior to blood 
draw. We show that elevated plasma oxysterols are associated with both cerebrovascular disease 
and incident CI. However, the discrepancies in the direction of associations between 27-OHC 
with cerebrovascular disease and with incident CI suggest cholesterol metabolism to oxysterols 
in the periphery differs between participants with cerebrovascular disease versus those who go 
onto develop to incident CI and these relationships are independent of concurrent circulating 
cholesterol levels.  
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To our knowledge, this is the first study to show that higher levels of plasma oxysterols 
are seen in cognitively normal participants with evidence of small vessel cerebrovascular 
disease. The differences occurred in cognitively normal individuals at least four years prior to the 
onset of cognitive impairment. However, these findings complement what we know about the 
structure and metabolism in the brain and may have implications to understanding the underlying 
metabolic changes occurring in the aging brain. White matter holds vast reserves of cholesterol 
(~28% of the dry weight)(Snipes and Suter 1997). Cholesterol provides insulation to the myelin 
surrounding the length of the axon(Snipes and Suter 1997). The integrity of the myelinated axon 
is essential to the speed of communication between neurons(Snipes and Suter 1997). 
Degradation of the myelin is believed to be a normal component of aging and is accelerated in 
cerebrovascular disease and AD(Bartzokis 2004). Myelin breakdown releases excess cholesterol 
into the extracellular space(Bartzokis 2009). Excess cholesterol in the brain stimulates its own 
conversion to 24-OHC in the neuronal body. The enzymatic oxidative metabolism of cholesterol 
to 24-OHC and its direct diffusion across the BBB is the primary means by which the brain 
eliminates excess cholesterol(Bjorkhem 2006). This process leads to higher levels of 24-OHC in 
the circulation(Bjorkhem 2006). Therefore, myelin breakdown resulting from cerebrovascular 
disease would provide a biologic basis for increasing cholesterol metabolism in the brain and 
higher levels of 24-OHC in the plasma. Plasma 24-OHC may be a sensitive marker of increased 
cholesterol metabolism occurring early in the neurodegenerative process. 
Additionally, excess cholesterol in the cell membrane has been shown to lead to the 
production of Aβ and its deposition as plaques in vitro(Fassbender and Stoick 2002). Therefore 
the brain must eliminate excess cholesterol to prevent Aβ formation. Our findings suggest 
increased oxidative cholesterol metabolism to 24-OHC production occurs prior to the onset of 
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cognitive symptoms in individuals who go onto develop incident cognitive impairment (MCI and 
AD). This result supports findings from studies of 24-OHC and neurodegenerative diseases as 
well prior cross-sectional studies of oxysterols and AD, MCI and dementia in the 
literature(Lutjohann, Papasotiropoulus et al. 2000; Kolsch and Heun 2004; Leoni 2009). This 
increased oxysterol formation is also seen in MCI, suggesting a shared pathway. Furthermore, 
our study examines the relationship between oxysterols, 24-OHC and 27-OHC, and the 
longitudinal development of cognitive impairment. Our findings suggest a temporal elevation in 
plasma 24-OHC occurs prior to the development of incident MCI and AD. These findings 
support the hypothesized trajectory of the 24-OHC across the neurodegenerative disease 
process(Leoni 2009) (Figure 3). 
Strengths of this study include the use of extensive measures of neurological disorders 
and cognition and the long follow-up time. Further, the CHS-CS participants were followed with 
repeat cognitive testing from 1998 to 2010. The small sample size of this study limits 
interpretation of the data. This study did not measure change in oxysterols over time. The 
hypothesized change in oxysterols over the dementia process is essential to assessing its validity 
as a marker and has yet to be investigated. We are currently completing the evaluation of the 
longitudinal change in oxysterols and its relationship to amyloid deposition in brain measured in 
vivo by PET scan using the Pittsburgh compound B (PiB-PET)(Price, Klunk et al. 2005).  
Measurement of oxysterols may provide information about cholesterol metabolism and 
brain disease preceding cognitive impairment. As a marker of excess cholesterol metabolism in 
the brain, plasma 24-OHC may also have applications to understanding beta amyloid 
neuropathology occurring early in the cognitive impairment process. It is possible that measures 
of oxysterols can provide a tool to investigate both drug and non-pharmacological interventions 
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that may affect cholesterol metabolism in brain and risk of AD. These novel associations need to 
be replicated in other larger elderly populations. Future research investigating oxysterols as 
potential markers of AD should consider the structural and metabolic changes occurring in the 
brain, in particular during the development of cerebrovascular disease and amyloid deposition. 
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Introduction: Excess brain cholesterol is a potential risk factor for Alzheimer’s disease (AD) 
and has been shown to lead to beta-amyloid (Aβ) formation and deposition as Aβ plaques. 
Cholesterol metabolism remains a target for dementia prevention and treatment with by lipid 
lowering drugs. We investigate the associations between markers of cholesterol metabolism in 
the brain and periphery with in vivo amyloid deposition and brain volumes  
Methods: Amyloid deposition and volumetric MRI were assessed in the brains of 200 non-
demented elderly participants from the Gingko Evaluation of Memory Study (GEMS). Plasma 
oxysterol levels and lipid profiles were measured in 183 participants within one year of imaging 
study.  
Results: At time of the neuroimaging sub-study participants had a mean age of 85 years, 41% 
were women, 19% were diagnosed with MCI and 55% were PiB-positive. Oxysterol metabolites 
of cholesterol from the brain and the periphery were not associated with volumetric MRI of the 
brain or PiB-PET in vivo. We found significant interaction between PiB-status and statin use on 
oxysterol levels, and also with gray matter volume. Among statins users, oxysterols from the 
brain were higher for PiB-positive as compared to PiB-negative participants.  
Conclusions. Future studies would need to examine the role of statins in mediating the 




The mechanisms underlying AD pathology are not well understood. Excess cholesterol 
and its metabolism in the brain remain a major research interests in dementia. Currently, 
intervention trials show statins have little promise in the treatment(McGuinness, O'Hare et al. 
2010) and prevention(McGuinness, Craig et al. 2009) dementia. The metabolism of cholesterol 
in the brain is a current important topic in dementia research. Oxysterol metabolites of 
cholesterol have been proposed as potential biomarkers of dementia and AD; yet their 
relationship with Alzheimer pathology remains unknown. The oxysterol, 24S-hydroxycholesterol 
(24-OHC) is the primary metabolite of cholesterol in the brain(Bjorkhem 2006). 24-OHC has 
been associated with various neurodegenerative diseases(Leoni 2009). Plasma levels of 24-OHC 
have been associated with AD(Bretillon and Siden 2000; Papassotiropoulus and Lutjohann 
2000), VaD(Lutjohann, Papasotiropoulus et al. 2000) and MCI as well as brain 
volume(Solomon, Leoni et al. 2009). However, the direction of the associations between AD and 
plasma 24-OHC are inconsistent.  
Recently, our group found that oxysterols are higher in cognitively normal participants 
with evidence of cerebrovascular disease visible on MRI and higher in those who developed 
cognitive impairment over 8 years of follow-up (Hughes, et al. unpublished 2011). The 
relationship between plasma 24-OHC and amyloid deposition in the brain remains unknown. 
Understanding the relationship between cholesterol metabolism in the brain in the context of 
underlying structural and biochemical changes occurring in the dementia process will: provide 
insight into the unknown underlying pathology of dementia and determine the usefulness of 
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oxysterols as surrogate markers and targets for interventions aimed at the prevention or treatment 
of dementia. Here we determine whether 24-OHC, a marker of cholesterol metabolism in the 




The Ginkgo Evaluation of Memory (GEM) study (2000-2008) was a multi-site, placebo-
controlled, double-blind, randomized clinical trial of daily use of Ginkgo biloba in 3069 
community-dwelling participants 72-96 years old. Exclusion criteria were reported in detail 
elsewhere (unpublished data, Snitz and Klunk) but included prevalent dementia, present use of 
cholinesterase inhibitors or other medication with significant psychotropic effects, recent 
hospitalization for depression, diagnosis of Parkinson disease, abnormal blood/serum tests at 
screening, or disease-limited life expectancy of <5 years. Median follow-up time from 
randomization was 6.1 years. Study visits occurred at 6-month intervals; a wide array of 
cognitive, genetic, functional, proxy-reported and medical history variables were collected 
(DeKosky, 2006). 
In 2009, approximately one year following the GEM study closeout, n=197 participants 
from the Pittsburgh site were recruited into the GEM Imaging Sub-Study. Sub-study participants 
went on to receive MR imaging and PiB-PET. The inclusion criterion was completion of the 
GEM Study protocol. Exclusion criteria were: 1) dementia at GEM Study close-out in 2008, and 
2) contraindications for neuroimaging (e.g., pacemaker). Comparisons to the 671 participants at 
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the Pittsburgh site have been detailed (unpublished data, Snitz and Klunk). Compared to all 671 
Pittsburgh site participants who completed the GEM Study protocol and did not reach a dementia 
endpoint, the Imaging Sub-Study participants were younger (mean±SD, 84.0±2.8 vs. 84.4±3.0 
years at close-out, p=0.03) but comparable in sex, race, education, ApoE4 status, estimated 
premorbid IQ and estimated income by zip code (p>0.05). Compared to all 966 Pittsburgh site 
participants at GEM Study baseline, they were younger, had higher estimated premorbid IQ 
(p<0.05) but did not differ by sex, race, education, ApoE4 status or estimated income by zip code 
(p>0.05) (unpublished data, Snitz and Klunk). 
 
Imaging Study 
MRI scanning used a Siemens 12-channel head coil and was performed on a 1.5T 
Siemens MR scanner at the MR Research Center of the University of Pittsburgh. Four series of 
MRI images were acquired on the MR scanner, these included magnetization-prepared rapid 
gradient echo (MPRAGE) T1-weighted images, fluid-attenuated inversion recovery (FLAIR) 
images, diffusion weighted images (DTI, b-values=0 and 1000 s/mm; 12 diffusion directions 
with four repeats), and two series of sagittal scans (with and without the off-resonance saturation 
pulse). A radiologist checked the MR images used in this study and excluded any unexpected 
findings from the study. 
 
Image Processing and Analysis 
Brain tissue volumes (gray matter, white matter, and cerebrospinal fluid), were calculated 
by segmenting the skull-stripped T1-weighted image in native anatomical space using the FAST 
- FMRIB's Automated Segmentation Tool (Zhang, Brady et al. 2001). The total gray matter 
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volume, white matter volume, and cerebrospinal fluid volume were estimated in cubic 
millimeters by summing all voxels classified as these tissue types. Total intracranial volume 
(ICV) was computed as the volume contained within the ‘inner skull’ using the brain extraction 
tool (BET)  with an advanced option (−A)(Jenkinson, Pechaud et al. 2005). White matter 
hyperintensity (WMH) were visualized from T2-weighted FLAIR image using an automated 
method for quantification and localization of WMH. The WMH quantification was done using a 
fuzzy connected algorithm with automated seed selection (Wu, Rosano et al. 2006). Total WMH 
volume was estimated by summing all the voxels classified as WMH and then normalized by 
brain volume. Segmented volumes of the gray matter (GM), white matter (WM), white matter 
hyperintensities (WMH) and cerebrospinal fluid (CSF) are shown as a ratio, adjusted for the total 
ICV.  
 
GEM Visit Assessments 
Sub-Study participants underwent a shortened visit which included an abbreviated 
neuropsychological (NP) battery, 10-question CES-D for depression, timed walk, and inventory 
of the participant’s prescription and over-the-counter medications. Statin use was assessed at 
each visit. For the purpose of this analysis participants were categorized as ever using statins and 
current statin use at their last recorded medication assessment.    
 
Cognitive Status 
Cognitive adjudication was completed blind to neuroimaging results by the GEM study 
Cognitive Diagnostic Center (DeKosky, 2006), taking into account historical serial cognitive 
assessments from the parent GEM Study. Criteria for mild cognitive impairment (MCI) included 
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1 - 3 tests impaired at cutoffs of 1.5 SD below age-education adjusted means. MCI was further 
subtyped according to Winblad et al. (2004). Four or more impaired tests resulted in a cognitive 
classification of 'dementia-level impairment’.  
 
Blood Draws 
All GEMS subjects who returned to the clinics for their final evaluation between October 
2007 and March 31, 2008 were requested to have blood drawn at their last visit. Of the 197 
participant in the GEM Imaging Sub-Study, 183 had plasma samples available at study close.  
 
Assay of Oxysterols and Cholesterol 
Single tubes for analysis of total plasma lipids and oxysterols were thawed once for each 
assay. Oxysterols (24S-hydroxycholesterol and 27-hydroxycholesterol) were assayed by isotope 
dilution using gas chromatography/mass spectroscopy (GC/MS)(Dzeletovic and Breuer 1995). 
Reproducibility and reliability of oxysterol measures were determined using a random selection 
of 14 samples in this analysis repeated one month apart. We obtained direct measures of lipids 
(total cholesterol, HDLc, triglycerides) and calculated LDLc from the same sample tubes.  
 
Statistical Analysis 
We investigated participant characteristics as potential covariates and determinants of 
oxysterol levels using ordinary least squares regression to obtain least squares means (LSmeans) 
and standard errors (SE) for each potential covariate. Potential neuroimaging determinants of 
oxysterols assessed in this study were: (1) PiB-status (positive or negative) using PiB-PET scan 
and (2) brain volumes on MRI (gray matter (GM), white matter (WM), white matter 
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hyperintensities (WMH) and total brain volume). Significance of differences of participant 
characteristics between PiB-status were assessed using t-tests and chi-squared tests. Correlations 
are shown as Spearman correlation coefficients. Multivariable logistic regression was used to 
estimate the association between PiB-positive versus PiB-negative participants in levels of 24-
OHC and 27-OHC. Covariates included in analyses were age and gender (model 1) plus current 
statin use at last visit (model 2). Because certain statins are known to affect oxysterol and lipid 
levels in the plasma, potential effect modification by statin use was assessed with interaction 
term (PiB status*statin use) in estimating mean oxysterol and lipid levels.  
Resulting individual p-values were considered significant if p-value <0.05. Interaction 
terms were considered significant at the p-value <0.10. The analytic sample size consisted of 183 
participants who received PiB-PET imaging, blood draw in 2009, and had viable measures of 
oxysterols and lipids. 
3.3 RESULTS 
At the time of blood draw and neuroimaging, participants had a mean age of 85 years, 74 
(40%) were women, 31 (17%) were ApoE-4 allele carriers, and 34 (18%) demonstrated mild 
cognitive impairment (MCI). The differences in characteristics between the imaging sub-study 
participants and the entire cohort have been described previously (Klunk and Snitz, unpublished 
data). Lipid measurements from stored blood samples in 2009 were available on 176 (96%) 
participants.  
Oxysterols were measured in 182 participants with mean(±SD) levels of 38(±12) ng/mL 
and 170(±48) ng/mL for 24-OHC and 27-OHC, respectively. Table 4 details the association 
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between participant characteristics and oxysterol levels. Measures of plasma oxysterols were not 
associated with age, ApoE-4 carrier status, MMSE, and MCI diagnosis. Plasma oxysterols were 
significantly associated with gender. Women in this study had higher levels of 24-OHC 
(p=0.003) and lower levels of 27-OHC (p=0.03). Plasma levels of 24-OHC were significantly 
correlated with plasma concentrations of total cholesterol (r=0.22) and HDLc (r=0.18), all 
p<0.05. Levels of 24-OHC were only marginally associated with LDLc (r=0.14, p=0.06) and not 
associated with triglycerides (r=0.005, p=0.89). Plasma levels of 27-OHC were not associated 
with cholesterol, HDLc, LDLc, triglycerides in the blood. 
Plasma concentrations of oxysterols were not significantly different between participants 
with MCI and those who were cognitively normal in 2009 (p=0.55); additionally levels of 24-
OHC did not differ by MMSE score (p=0.16). Participants using statins at their last visit had 
significantly lower levels of 27-OHC (p<0.01) and marginally lower 24-OHC (p=0.08). The 
interaction term between cognitive status and statin use predicting 24-OHC was significant 
(p=0.02) indicating that levels of 24-OHC are lowest in cognitively normal statin users and 
highest in statin users with MCI (p<0.01). 
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Table 4: Cross-sectional associations between participant characteristics and oxysterol levels.  
       24-OHC 27-OHC 
    n LSmeans p-value LSmeans p-value 
Age  
      
 
<85 52 37.9 0.6479 176.2 0.6057 
 
85-86 53 35.0 0.0995 167.4 0.7118 
 
86-87 36 39.5 0.8503 165.3 0.5984 
 
>87 41 39.0 ref 171.0 Ref 
Gender 
      
 
Men 108 35.5 0.003 176.4 0.0347 
 
Women 74 40.7 ref 161.3 Ref 
ApoE 
      
 
No e-4 121 37.5 0.2109 172.9 0.6857 
 
e-4 33 40.4 ref 169.1 Ref 
MMSE_7 
      
 
<28 106 38.2 0.1646 169.4 0.8077 
 
≥28 66 35.7 ref 171.2 Ref 
Diagnosis 
      
 
Normal 148 37.4 0.5501 171.1 0.6373 
 
MCI 34 38.0 ref 166.8 Ref 
Treatment group 
     
 
Plaeb 91 37.6 0.9718 175.9 0.0975 
 
Active  91 37.7 ref 164.2 Ref 
Statins 
      
 
No statin 95 39.1 ref 179.6 Ref 
 
Ever  87 36.1 0.0879 164.3 0.1198 
  Current 69 35.7 0.0789 154.5 0.0004 
*p-values unadjusted 
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The associations between plasma oxysterols and segmented brain volumes are presented 
in Table 5. In linear models, volume of WMH/ICV was marginally correlated with 24-OHC 
(p=0.09); gray matter, white matter and total brain volume showed no suggestion of association 
with 24-OHC in linear models. Expressed as quartiles, brain volumes were not associated with 
oxysterols. The relationship between plasma 24-OHC and quartiles of WMH/ICV appears to be 
U-shaped, with lower levels of 24-OHC in the bottom and upper quartiles and higher in the 
middle two quartiles. The lowest category of WM/ICV volumes was marginally associated with 
24-OHC (p=0.07). Despite not approaching significance, monotonic declines in mean levels of 
oxysterols were visible across categories of WM/ICV volumes. Segmented brain volumes were 




Table 5: Associations between oxysterols and segmented brain volumes (n=158) 
     24-OHC 27-OHC ratio 24/27-OHC 
    LSmeans SE P-VALUE LSmeans SE P-VALUE LSmeans SE P-VALUE 
White matter / ICV 
         
 
Q1 35.3 1.8 0.083 164.8 7.8 0.574 0.23 0.01 0.484 
 
Q2 38.9 1.8 0.671 167.1 7.7 0.702 0.25 0.01 0.758 
 
Q3 38.6 1.8 0.592 169.1 7.7 0.845 0.24 0.01 0.708 
 
Q4 40.0 1.9 ref 171.3 8.2 ref 0.24 0.01 ref 
 
trend 0.334 0.949 0.7552 







Gray matter / ICV 
         
 
Q1 37.6 1.8 0.793 177.2 7.7 0.507 0.23 0.01 0.769 
 
Q2 38.3 1.8 0.994 167.3 7.7 0.826 0.24 0.01 0.742 
 
Q3 38.2 1.9 0.965 156.3 7.9 0.216 0.26 0.01 0.154 
 
Q4 38.3 1.9 ref 169.7 7.9 ref 0.23 0.01 ref 
 
trend 0.992 0.31 0.3504 







CSF  / ICV 
         
 
Q1 35.0 1.8 0.175 171.9 7.7 0.473 0.22 0.01 0.155 
 
Q2 40.9 1.8 0.356 174.5 7.6 0.343 0.25 0.01 0.994 
 
Q3 37.7 1.8 0.728 160.0 7.8 0.717 0.24 0.01 0.776 
 
Q4 38.5 1.9 ref 163.9 8.0 ref 0.25 0.01 ref 
 
trend 0.136 0.5285 0.4179 



















WMH / ICV 
 
Q1 35.9 1.9 0.520 160.8 7.9 0.510 0.24 0.01 0.559 
 
Q2 39.3 1.8 0.525 181.3 7.6 0.238 0.23 0.01 0.970 
 
Q3 39.3 1.8 0.524 161.3 7.5 0.523 0.25 0.01 0.233 
 
Q4 37.6 1.9 Ref 168.3 7.8 ref 0.23 0.01 Ref 
 
trend 0.490 0.187 0.581 







WMH / WM 
         
 
Q1 36.2 1.9 0.540 165.8 7.7 0.664 0.24 0.01 0.796 
 
Q2 40.8 1.8 0.272 181.1 7.5 0.336 0.24 0.01 0.561 
 
Q3 38.1 1.8 0.901 159.5 7.3 0.304 0.25 0.01 0.385 
 
Q4 37.8 1.9 Ref 170.7 7.7 ref 0.23 0.01 Ref 
 
trend 0.347 0.207 0.8302 
Interaction with statins   0.576     0.167     0.513 
*Adjusted for age and gender 
** Model 2: adjusted for age, gender, statin use, interaction statin use and volume 
Cerbrospinal fluid (CSF), intracranial volume (ICV) 
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Table 6 presents the sample characteristics of the n=182 participants in the analytic 
sample by PiB-Status. In non-demented participants included in this study, 101 (55%) were PiB-
positive. Participants PiB-positive were more likely have taken gingko biloba during the trial 
(p=0.05), ApoE-genotype (p<0.01) and to have mild cognitive impairment (MCI) (p<0.01).  
 
 
Table 6: Cross-sectional associations between participant characteristics and PiB-Status. 
 




positive   
  
(n=182) (n=81) (n=101)       p-value 
    n % n % n % unadjusted  







<85 52 28.6 25 30.9 27 26.7 0.534 
 
85-86 53 29.1 23 28.4 30 29.7 0.889 
 
86-87 36 19.8 15 18.5 21 20.8 0.710 
 
>87 41 22.5 18 22.2 23 22.8 ref 
Women 
 




     
0.006 
 
e22 1 0.5 1 1.2 0 0.0 
 
 
e23 19 10.4 13 16.0 6 5.9 
 
 
e24 1 0.5 0 0.0 1 1.0 
 
 
e33 101 55.5 48 59.3 53 52.5 
 
 
e34 31 17.0 4 4.9 27 26.7 
 MMSE  
 







<27 44 24.2 14 17.3 30 29.7 0.054 
 
27-28 62 34.1 27 33.3 35 34.7 0.877 
 
28-30 36 19.8 18 22.2 18 17.8 0.437 
 
>30 30 16.5 16 19.8 14 13.9 ref 
Diagnosis 
 
    
 
  
   
 
Normal 148 81.3 73 90.1 75 74.3 0.008 
 
MCI 34 18.7 8 9.9 26 25.7 







Active 91 50.0 34 42.0 57 56.4 0.053 







Ever statin 87 47.8 49 60.5 38 37.6 0.830 
  Current statin 69 37.9 37 45.7 32 31.7 0.692 
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Table 7 presents the levels of plasma oxysterols and lipid by PiB-status. Plasma 
oxysterols and lipids levels were not associated with PiB-status. However the lower levels of 
oxysterol levels in the plasma of statin users resulted in a significant interaction term between 
PiB-status and statin use predicting plasma oxysterols. 
 
Table 7: Cross-sectional associations between lipid components and PiB-status 
        Total PiB-negative PiB-positive   
  
n n=182 n = 81 n = 101 p-value 




    
 
  
 24-OHC  (ng/mL) 182 37.6 11.7 37.2 11.1 38.1 12.2 0.651 
27-OHC  (ng/mL) 182 170.0 47.6 173.1 45.9 168.0 49.0 0.475 
Ratio_24/27 182 0.23 0.09 0.23 0.09 0.24 0.10 0.272 
Cholesterol (mg/dL) 176 163.1 32.1 163.1 33.1 162.6 31.2 0.918 
LDL (mg/dL) 176 87.9 27.6 88.5 29.6 87.1 25.9 0.733 
HDL (mg/dL) 176 49.2 13.4 47.6 12.6 50.3 13.9 0.179 
Triglycerides (mg/dL) 176 131.3 62.3 135.0 60.5 128.3 64.3 0.481 
           
 
Table 8 shows effect of statin use on the levels of oxysterol and lipids by PiB status. 
Participants using statins at their last visit had significantly lower levels of 27-OHC regardless of 
PiB-status (p<0.001). A significant trend in the levels of 27-OHC were found across the 
interaction groups. Levels of 27-OHC were highest in PiB-positive/no statin, followed by PiB-
negative/no statin, and lowest in PiB-negative/statin groups. Participants using statins at last visit 
and were PiB-negative at PET scan had significantly lower levels of 24-OHC than participants 
not taking statins(p<0.05). Figure 5 shows the levels of 24-OHC among statins users was 
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significantly affected by PiB-status. PiB-negative participants taking statins had significantly 
lower (p<0.05) levels of 24-OHC than PiB-positive participants taking statins. 
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Table 8: Associations between oxysterols and PiB-status stratified by current statin use 
  
  
     No Statin Use (n=113) Statin Use (n=69)   
  
PiB-negative PiB-positive PiB-negative PiB-positive  
 
  
(n=49) (n=64) (n=32) (n=37) Overall    
p-value     LSmeans SE p-value LSmeans SE p-value LSmeans SE p-value LSmeans SE p-value 
24-OHC (ng/mL) 




Model 1 39.8 1.7 ref 38.1 1.5 0.429 33.2 2.1 0.013 37.9 1.9 0.437 0.092 
 
Model 2 40.7 1.6 ref 38.3 1.4 0.285 33.7 2.0 0.008 38.4 1.9 0.355 0.082 
               27-OHC (ng/mL) 
             
 
Model 1 187.2 6.6 ref 173.9 5.8 0.129 151.5 8.1 0.001 158.0 7.6 0.004 0.003 
 
Model 2 185.0 6.6 ref 173.1 5.7 0.173 150.4 8.1 0.001 156.4 7.6 0.005 0.003 
               Ratio 24/27-OHC 
             
 
Model 1 0.22 0.01 ref 0.23 0.01 0.476 0.23 0.02 0.629 0.25 0.02 0.129 0.505 
 
Model 2 0.23 0.01 ref 0.24 0.01 0.7 0.24 0.02 0.744 0.26 0.01 0.155 0.532 
               Total cholesterol 
(mg/dL) 
             
 
Model 1 160.7 4.6 ref 167.7 4.1 0.257 166.6 5.7 0.420 153.8 5.3 0.331 0.177 
 
Model 2 163.9 4.4 ref 168.6 3.8 0.424 168.2 5.4 0.537 156.6 5.0 0.278 0.259 
               LDLc (mg/dL) 
             
 
Model 1 86.4 4 ref 89.6 3.5 0.549 91.7 5.0 0.404 82.8 4.6 0.562 0.538 
  Model 2 88.3 4 ref 90.0 3.5 0.746 92.9 4.9 0.469 84.3 4.5 0.511 0.617 
Model 1: unadjusted 
         
  
  Model 2: adjusted for age and gender 




Figure 5: Concentrations of plasma 24S-hydroxycholesterol (ng/mL) by PiB-Status and current statin use. 
 
3.4 DISCUSSION 
In this population of non-demented elderly participants, the levels of plasma oxysterols, 
24-OHC and 27-OHC, were not significantly associated with having PiB-positive PET scans. 
Any relationship between PiB status and oxysterols was highly dependent on the concurrent use 
of statins. Participants using statins tended to have lower levels of 24-OHC and significantly 
lower levels of 27-OHC in the plasma. Statin use modified the relationship between 24-OHC and 
PiB-status. Specifically, the levels of 24-OHC were significantly lower in participants who were 
PiB-negative and taking statins. Interestingly participants taking statins but were PiB-positive 
had approximately the same levels of 24-OHC as those not taking statins. In this study plasma, 
oxysterol levels were not significantly different between normal and MCI participants. This 
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differs from our earlier findings in CHS-CS and the findings of other studies in the literature that 
report that levels of plasma 24-OHC tend to be higher in MCI participants compared to normal 
controls(Lutjohann, Papasotiropoulus et al. 2000; Papassotiropoulus and Lutjohann 2000). Few 
studies adjust for the effects of statin use on plasma oxysterol levels in studies of AD. Statins are 
thought to suppress oxysterol production through inhibition of its cholesterol precursors. This is 
evident by the significantly lower levels of 27-OHC in statin users regardless of PiB-status.  
A limitation of this study is that the specific statin used by each participant was not taken 
into account. All statins were considered as a single group. Statins are shown to suppress 
oxysterol levels in the plasma. It is believed that statin able to cross the BBB can suppress 
cholesterol synthesis in the brain. Potent statins, simvastatin (Locatelli and Lutjohann 2002), 
lovastatin(Vega and Weiner 2007) have been shown to cross the blood brain barrier and suppress 
cholesterol synthesis in the brain and lower levels of 24-OHC in the plasma. Not all statins have 
the ability to cross the blood brain barrier due to their relative lipophilicity. Other statins, such as 
pravastatin, have do not decrease plasma 24-OHC levels(Thelen and Laaksonen 2006). Despite 
the documented effects of statins on oxysterol levels, few studies account for these effects by 
adjusting, stratifying or restricting analysis based on statin use. 
 
Conclusions 
Plasma oxysterols, 24-OHC and 27-OHC, are non-invasive markers of enzymatic 
cholesterol metabolism in the brain and the periphery, respectively. Oxysterols can be measured 
in fresh and stored plasma or serum samples. Cross-sectional associations between 24-OHC and 
PiB-PET indicate a limited potential relationship between cholesterol metabolism in the brain 
and Aβ deposition as plaque in elderly participants. Statin use likely modifies the relationship 
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between PiB-status and oxysterol levels, indirectly through the suppression of cholesterol 
synthesis. Longitudinal measures of oxysterols over nine years (baseline and 2009 of GEMS) 
will provide insight into the potential changes of cholesterol and cholesterol metabolism 




4.0  DISSERTATION DISCUSSION 
4.1 OVERALL SUMMARY OF FINDINGS 
Our review of the literature indicates inconsistent associations between brain-derived 
plasma oxysterols and AD. Epidemiological design and methodological limitations may explain 
these conflicting results. Potential methodological issues include: residual confounding, lack of 
temporal associations, and inconsistent direction of associations resulting from stage of the 
disease at which oxysterols were measured. Few studies of oxysterols and cognitive impairment 
seek to identify potential confounders and adjust for them in analyses. A wide survey of the 
literature focused on oxysterols and neurodegenerative disease indicates that 24-OHC is 
associated with: age, global cognition scores, severity of disease, gender, statin use and ApoE-4 
carrier status. Many of these characteristics are also established risk factors for cognitive 
impairment; however, associations between oxysterols and cognitive impairment reported in the 
literature do not attempt to adjust for these potential confounders. These studies mostly rely on 
case-control design and often select participants from hospitals and memory clinics. These cross-
sectional studies lack crucial information about temporality of these associations. It remains 
uncertain whether the relative differences in plasma concentrations of oxysterols between cases 
and controls occurs prior to cognitive impairment or as a result of these neurodegenerative 
processes. Studies of oxysterols and longitudinal evaluation of cognition suggest that plasma 
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oxysterols are associated with baseline speed of processing but unrelated to concurrent cognitive 
tests or changes in cognition over six years of follow-up. Furthermore, studies of oxysterols and 
cognitive impairment have yet to report the trajectory of oxysterols over the dementia process.  
Studies of oxysterols and other neurodegenerative diseases suggest that plasma levels of 
24-OHC increase early in the disease process. Careful review of the literature shows that 24-
OHC tends to be higher in individuals with cognitive impairment than cognitively normal 
controls when measured early in the disease process. Plasma 24-OHC is negatively correlated 
with global scores and severity of disease; therefore the levels of 24-OHC are lower in 
participants with a long duration of dementia. Despite these inconsistencies of direction seen in 
the literature, studies of oxysterols that measure both dementia and MCI outcomes have good 
internal validity. These studies show that plasma 24-OHC measured in patients with AD, VaD 
and MCI are always in the same direction of association compared to controls.     
A major methodological limitation of the literature is the scarcity of objective measures 
to quantify underlying structural changes occurring the aging and AD brain. Magnetic resonance 
imaging (MRI) and positron emission tomography (PET) are used to provide quantitative 
markers of underlying brain changes occurring well before the onset of the clinical disease. Our 
original research addresses this knowledge gap by examining the longitudinal association 
between oxysterols, cognition and brain imaging markers. In our first study, we found that higher 
levels of brain-derived oxysterols were associated with MRI markers of cerebrovascular disease 
and with greater risk of incident cognitive impairment over 8 years of follow-up. The levels of 
both 24-OHC and 27-OHC were both higher in cognitively normal older participants with the 
presence of higher grade white matter hyperintensities and infarcts compared to those without 
evidence of cerebrovascular disease. Furthermore, higher levels of 24-OHC, but not 27-OHC, 
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were associated with the development of incident cognitive impairment, including both the 
incident diagnosis of AD and MCI. These associations between oxysterols and cerebrovascular 
disease and incident cognitive impairment were independent of age, gender, and statin use. In the 
case of cerebrovascular disease, we found these associations to also be independent of concurrent 
total cholesterol levels. We also found that oxysterols were not associated with MRI and genetic 
markers of AD risk in cognitively normal elderly participants in this study. In our second study 
of oxysterols and underlying AD pathology, we found that oxysterol levels were not associated 
with the presence of significant amyloid deposition in the brains of cognitively normal and MCI 
elderly participants. We found that the use of lipid-lowering drugs may modify any association 
between plasma oxysterols levels and in vivo amyloid deposition in the general population freely 
taking statins.  
 
4.2 PUBLIC HEALTH SIGNIFICANCE  
 
The antecedents and neurodegenerative processes underlying dementia remain unclear. 
Cholesterol metabolism is believed to be an important factor in the initiation and progression of 
AD. The alteration of brain cholesterol synthesis and metabolism are current intervention targets 
for the prevention and treatment of dementia. Our research adds important evidence that 
cholesterol metabolites are more strongly associated with the presence of cerebrovascular disease 
than markers of AD pathology preceding cognitive impairment. Cerebrovascular disease 
occurring in the white matter of the brain may indicate myelin breakdown. Myelin breakdown 
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leads to the release of vast stores of cholesterol residing in the myelin. It is possible that higher 
diffusion of brain-derived metabolites of cholesterol across the BBB and into the circulation is a 
reaction to states of excess cholesterol in the brain. In vitro studies demonstrate that excess 
cholesterol in plasma membranes leads to Aβ production and deposition in the brain. Our study 
of oxysterols and in vivo amyloid imaging brain indicates that brain-derived oxysterols are not 
associated with Aβ deposition in non-demented elderly participants. We found that brain-derived 
oxysterols were elevated prior to the onset of cognitive impairment, particularly in those with 
cerebrovascular disease. Brain-derived oxysterols may be a useful marker of dementia risk, early 
in the dementia process; oxysterols may provide prognostic information late in the course of 
disease.   
 
4.3 STRENGTHS AND WEAKNESSES  
A particular strength of this research is that it examines the relationship between 
oxysterols and dementia without relying solely on the diagnosis of cognitive impairment. Our 
studies utilize cutting edge neuroimaging techniques to image the underlying structural changes 
occurring in the cognitive impairment processes. We also utilize cognitively normal participants 
at baseline to examine the temporal associations between oxysterols and incident cognitive 
impairment.  
A limitation of this research is that oxysterols are only surrogate markers of cholesterol 
metabolism in the brain. It is unknown of elevations in oxysterols reflect innate cholesterol 
excesses or increased metabolism due to recent increases in cholesterol concentrations in the 
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brain, or other reasons that remain unknown. However, 24-OHC is the primary metabolite of 
cholesterol in the brain. Conversion of cholesterol to 24-OHC is suspected to increase during 
active myelination and repair. 24-OHC is also expected to increase cholesterol load in ApoE 
indirectly through the binding to LXR and up regulation of ABCA1 which in turn increases 
cholesterol density within ApoE. ApoE is the main transporter of cholesterol in the brain and the 
primary genetic risk factor for AD.        
      
 
4.4 FUTURE RESEARCH   
Our findings raise interesting questions regarding the role of cholesterol metabolism in 
the brain and in the dementia process. While we show that oxysterols are significantly higher in 
participants with evidence of cerebrovascular disease and not associated with amyloid deposition 
in the brain, these findings are novel and need to be replicated in larger studies with younger 
participants. In particular, individuals with familial hypercholesterolemia and individuals with 
familiar risk for AD and cerebrovascular disease would be ideal study groups. It is unknown if 
higher levels of oxysterols are a result of or antecedent for cerebrovascular disease. Although we 
did not find a relationship between oxysterol metabolites of brain cholesterol and amyloid 
deposition using PiB-PET, it is possible that oxysterols may be related to PiB-status in younger 
individuals. The mechanisms leading to amyloid deposition in the brain of exceptionally fit 
elderly participants is likely different from younger participants at risk for AD. Another group 
with particular relevance to this research area are aging individuals with multiple sclerosis. 
Successful treatments have extended the life-expectancy of MS patients to near normal life 
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expectancy of the general population. We don’t yet understand the effect of chronic 
demyelination on the aging brain and the risk for dementia it may impose.              
 
4.5 FINAL CONCLUSIONS 
Brain-derived plasma oxysterols may be an important marker of cholesterol metabolism 
in the brain, underlying cerebrovascular disease, and an early marker of risk for the development 
cognitive impairment. Measuring brain cholesterol metabolites is feasible, relatively inexpensive 
and it could be used to assess the risk of developing cognitive impairment in a wide array of 
groups. Future studies investigating the relationship between oxysterols and dementia should: 
determine the longitudinal trajectory of oxysterol over the dementia process; obtain concurrent 
measures of brain structure and clinical signs of cognitive impairment, including serial MRI and 
PiB-PET; and access and control for confounding effects of lipid-lowering agents.   
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APPENDIX 
TABLES FROM REVIEW OF CHOLESTEROL METABOLISM TO OXYSTEROLS IN THE BRAIN AND DEMENTIA 
Table A1: Genetic variability studies in of enzyme responsible for conversion of cholesterol to 24S-hydroxycholesterol 
AUTHOR STUDY DESIGN SAMPLE SIZE RESULTS MEASURES 




AD patients = 455 
Controls = 327 
2 of 16 SNPs in CYP46A1 associated with 
AD. Haplotype of carriers showed reduced 
CSF levels of 24-OHC and total Chol. 
Oxysterols: 24-OHC & 27-
OHC (CSF) 
Genotyped: 16 SNPS in 
the CYP46A1 gene 
Outocome: Case status 
Kolsch H et al. 
(2002)(Kolsch, 





Controls = 144 
AD = 114 
Age mean: 71±8 years 
SNPs in the CYP46 gene may predispose to 
AD by increasing the R_24SOH ratio in the 
brain (CSF) 
Oxysterols: 24-OHC & 27-
OHC (CSF) 
Genotyped: SNPs in the 
CYP46 gene 
Outcome: Case status 
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Table A2:  Studies relating24S-hydroxycholesterol and various neurodegenerative diseases 
AUTHOR STUDY DESIGN SAMPLE SIZE RESULTS MEASURES 
Leoni et al. 
(2008)(Leoni and 
Mariotti 2008) 
Case-control Participants: 196 Total 
Controls = 67, 
HD-positive = 96, 
Pre-HD = 33 
Plasma 24-OHC were significantly higher in 
controls than HD patients. Levels of 24-OHC 




Outcomes: Case status, 
Volumetric MRI of caudate 
Leoni et al. 
(2002)(Leoni and 
Masterman 2002) 
Case control Participants: 301 
MS patients = 118 
Age matched controls = 
183 
 
Among MS patients levels of 24-OHC were 
higher in younger participants and 
associated with higher disability scores. 
Increased levels of 24-OHC seen only in 
lesion confirmed active disease. 
Oxysterols: 24-OHC 
(plasma and CSF) 
Outcomes: Case status 
Leoni et al. 
(2004)(Leoni, 





Controls = 58, MS = 88,  
AD = 54, Demyelinating 
= 21, hemorrhage = 8, 
viral meningitis = 12, 
borrelia = 14. 
Patients with active demyelinating diseases 
had highest levels of 24-OHC in the CSF, 
followed by viral meningitis, MS, and AD 
Oxysterols: 24-OHC and 
27-OHC (plasma and CSF) 
Outcomes: Case status 





Occlusion of middle 
cerebral artery = 4 
Occlusion of posterior 
cerebellar  artery = 2 
No controls 
Levels of cholesterol and oxysterols did not 
vary significantly in the days following 
admission to hospital for stroke symptoms 
indicating that oxysterols are of limited value 
for assessing BBB function in acute 
ischemic stroke patients. 
Oxysterols: 24-OHC and 
27-OHC (plasma) 
 






Participants: total = 97 
Controls = 37, MS = 60 
(20 RR, 20 SP, 20 PP) 
Serum R_24-OHC and cholesterol 
precursors were lower in MS subtypes than 
healthy controls 
Oxysterols: 24-OHC and 
27-OHC (serum) 
Outcomes: Case status 
Teunissen et al. 
(2003.b)(
Teunissen, 
Lutjohann et al. 
2003) 
Case-control Participants: 
AD = 34 
PD = 46 
OCD = 46 
Controls = 61 
Serum R_24-OHC found to be a significant 
predictor of neuro-cognitive disease. Not 
included in the final model of combined 
markers predicting neuro-cognitive disease. 
Oxysterols: 24-OHC and 
27-OHC (plasma) 
Outcomes: Combined 
case status (AD, PD, and 
OCD) 




Controls (age/sex) = 205 
AD = 40; MS = 20; 
Guillian-Burre = 4; 
Meningitis = 11; Primary 
gliomas = 7; Brain death  
= 11 
Patients with brain death and AD had 
significantly lower plasma 24-OHC than 
controls; no differences were seen for MS, 
ischemic stroke and primary brain tumors. 
Oxysterols: 24-OHC 
(plasma) 
Outcome: Case status 
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Table A3: Studies relating 24S-hydroxycholesterol to structural brain measures 
AUTHOR STUDY DESIGN SAMPLE SIZE RESULTS MEASURES 
Solomon A. et al. 
(2009)(Solomon, 
Leoni et al. 2009) 
Case-control Participants: 
SCI = 33 
MCI = 36 
AD = 27 
Mean age =  62 years 
Ratio 24-OHC/Chol and 27-OHC/Chol were 
significantly lower in AD patients. Adjusted 
for age, sex, ApoE and statins, the 
significant relationship between R_24-OHC 
to grey matter volume only seen in controls. 
Oxysterols: 24-OHC & 27-
OHC  (Plasma) 
Outcomes: Volumetric 
MRI yielding fraction 
volumes of: CSF, gray 
matter, and white matter. 






volunteers = 69 
Mean age = 50±13 
 
Participants with high levels of 24-OHC and 
27-OH also had larger hippocampal 
volumes. 24-OHC, not 27-OH, significantly 
predicts hippocampal volume. 
Oxysterols: 24-OHC & 27-
OHC (Plasma) 
Outcomes: Volumetric 
MRI (1. 5T) yielding, total, 
intracranial, and 
hippocampal volume 




Controls = 67 
HD-positive = 96 
pre-HD = 33 
Mean age = 46 years  
Plasma levels 24-OHC significantly higher in 
controls than HD patients. Levels of 24-OHC 




Outcomes: MRI of 
Caudate 
Karrenbauer et al. 
(2005)(Karrenbauer 




RR = 27 
PP = 19 
Controls = 23 
Ages: 23-58 years 
Plasma ratio of 24-OHC/chol negatively 
correlated with age (in both RR and PP 
patients) and volume of T2 lesions in RR 
patients (a marker of disease extent) 
Oxysterols: 24-OHC 
(Plasma) 
Outcomes: MRI T1 and T2 
lesions and gadolinium 
positive lesions 
Leoni V et al. 
(2002)(Leoni and 
Masterman 2002) 
Case control Participants: 
MS patients = 118 
Control = 183 
Ages: 21-70years 
Among MS patients levels of 24-OHC were 
higher in younger participants and were 
associated with higher disability scores. 
Increased levels of 24-OHC seen only in 
lesion confirmed active disease. 
Oxysterols: 24-OHC 
(plasma and CSF) 
Outcomes: Case status 





Participants: n = 20 
Decedent = 20 
 
Concentrations of cholesterol precursors 
were significantly higher in younger versus 
older participants. Absolute levels of 24-
OHC were slightly lower in hippocampus 
specimans from older participants 






Table A4: Case-control studies using diagnostic outcomes 
AUTHOR STUDY DESIGN SAMPLE SIZE RESULTS MEASURES 
Shafaati M et al. 
(2007)(Shafaati, 






Controls = 43 
AD = 17 
MCI = 20 
Ages: 18 – 85 years 
Levels of ApoE correspond to levels of 24-
OHC in AD cases but not controls. These 
results are consistant with 24-OHC and 
ApoE coupling seen in neurodegeneration 
Oxysterols: 24-OHC and 
27-OH (CSF) 
Stratification: Case status 
Outcomes: ApoE levels 
Leoni V et al. 
(2006)(Leoni, 




AD = 18 
MCI = 20 
Controls = 35 
Ages: 49 – 85 years 
CSF levels of 27-OHC and 24-OHC were 
significantly higher in MCI and AD than in 
controls. Differences between MCI and AD 
were not significant 
Oxysterols: 24-OHC 
(plasma and CSF) 
Outcomes: Case status 
(AD, MCI, controls) 
Kolsch et 
al.(2004)(Kolsch 
and Heun 2004) 
Case-controls Participants: 
AD = 134 
VaD = 24 
MCI = 36 
Depressed = 13 
Controls = 43 
Mean age: ~69 years 
Plasma ratio of 24-OHC/chol and 27-
OHC/chol reduced in AD, VaD and MCI 
compared to depressed participants and 
controls. Higher ratio of 24-OHC/27-OHC 
seen in AD, VaD and MCI compared to 
controls. 
Oxysterols:Plasma 24-
OHC and 27-OH (plasma) 
Outcomes: Case status 
Leoni V et al. 
(2004)(Leoni, 






Controls = 58 
AD = 54 
Other nerudegenerative 
disease = 143 
Mean age: controls = 39 
AD = 72 years 
Patients with active demyelinating diseases 
had highest levels of 24-OHC in the CSF, 
followed by viral meningitis, MS, and AD 
Oxysterols: 24-OHC and 
27-OH (plasma and CSF) 
Outcomes: Case status 




Controls = 15 
AD = 15 
Ages: 61 – 92 years 
24-OHC was significantly increased in AD 
patients, specifically in the frontal cortex. 
The ratio of 24- to 27-OHC was elevated in 
AD patients 
Oxysterols: 24-OHC (CSF 
from brain samples) 
Outcomes: Case status 
Teunissen et al. 
(2003.b)(Teunissen, 
Lutjohann et al. 
2003) 
Case-control Participants: 
AD = 34 
PD = 46 
OCD = 46 
Controls = 61 
Ages = 42–95 years 
Serum R_24-OHC found to be a significant 
predictor of neuro-cognitive disease. Not 
included in the final model of combined 
markers predicting neuro-cognitive disease. 
Oxysterols: 24-OHC and 
27-OH (plasma) 
Outcomes: Combined 
case status (AD, PD, and 
OCD) 
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Table A4:  (continued) 
AUTHOR STUDY DESIGN SAMPLE SIZE RESULTS MEASURES 




Controls = 19 
AD = 25 
Elevated levels of 24-OHC found in the 
CSF, not plasma, of AD treated patients 
compared to controls. 
Oxysterols: 24-OHC 
(CSF and plasma) 
Outcomes: Case status 
Lutjohann et al. 
(2000)(Lutjohann, 
Papasotiropoulus et al. 
2000) 
Case-control Participants: 
Controls = 30 
AD = 30 
Depressed = 18 
Vascular AD = 12 
Ages: 48 – 87 
Plasma levels of 24-OHC were elevated in 
AD and VaD participants compared to 
normal  regardless of ApoE-4 genotype 
Oxysterols: 24-OHC 
(plasma) 
Outcome: Case status 
severity of disease using 
MMSE score 
Papassotiropoulus et al. 
(2000)(Papassotiropoulus 





AD  = 53(18 with mild 
AD) 
Mean age: ~ 73 years 
Severity of AD and inheritance of the 
ApoE-4 allele were independently 
associated with reduced plasma 24-OHC. 
Oxysterols: 24-OHC 
(plasma) 
Outcome: Case severity 
of disease using MMSE 
score 




AD = 40 (51-80 years of 
age) 
Controls = 205 (21 – 86 
years of age) 
Other brain disease = 
68 (28 – 82 years of 
age) 
Patients with brain death and AD had 
significantly lower plasma 24-OHC than 
controls; no differences were seen for MS, 
ischemic stroke and primary brain tumors. 
Oxysterols: 24-OHC 
(plasma) 





Table A5: Longitudinal studies of cognition 
AUTHOR STUDY DESIGN SAMPLE SIZE RESULTS MEASURES 
Teunissen et al. 
(2003)(Teunissen 
and De Vente 
2003) c 
Longitudinal Participants: 
Baseline = 92 
Follow-up = 116 
Both = 65 
Higher R_24-OHC levels were related to 
slower speed of processing, but not other 
cognitive tests. Higher ratio of cholesterol 
precursors associated with poor cognitive 
performance 
Oxysterols: 24-OHC and 
27-OH (plasma) 
Outcomes: Cognitive test 
for verbal learning and 
memory 
van den Kommer 
et al. (2009)(van 
den Kommer, Dik 




Baseline = 1181 
Follow-up = 1003 
Low Chol in 65 and older is an independent 
predictor of cognitive declines over 6 years. 
Ratios of 24-OHC/Chol and24-OHC/Chol 
significantly lower in ApoE-4 carriers. ApoE-
4 potential moderator of association 
between ratio 24-OHC/Chol and speed of 
processing. ApoE-4 status, R_24-OHC and 
R_27-OHC showed no association to 
cognitive decline. Only the ratio 27-
OHC/Chol inversely associated with 
performance on MMSE and immediate 
recall tests in ApoE-4 carriers 
Oxysterols: 24-OHC & 27-
OHC 
Outcomes: Cognitive 
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